false
FY
2023
0000792935
0000792935
2023-01-01
2023-12-31
0000792935
2023-06-30
0000792935
2024-05-06
0000792935
2023-12-31
0000792935
2022-12-31
0000792935
us-gaap:SeriesBPreferredStockMember
2023-12-31
0000792935
us-gaap:SeriesBPreferredStockMember
2022-12-31
0000792935
2022-01-01
2022-12-31
0000792935
us-gaap:SeriesAPreferredStockMember
2021-12-31
0000792935
us-gaap:CommonStockMember
2021-12-31
0000792935
us-gaap:AdditionalPaidInCapitalMember
2021-12-31
0000792935
grst:DiscountToParValueMember
2021-12-31
0000792935
us-gaap:ComprehensiveIncomeMember
2021-12-31
0000792935
us-gaap:RetainedEarningsMember
2021-12-31
0000792935
us-gaap:NoncontrollingInterestMember
2021-12-31
0000792935
2021-12-31
0000792935
us-gaap:SeriesAPreferredStockMember
2022-12-31
0000792935
us-gaap:CommonStockMember
2022-12-31
0000792935
us-gaap:AdditionalPaidInCapitalMember
2022-12-31
0000792935
grst:DiscountToParValueMember
2022-12-31
0000792935
us-gaap:ComprehensiveIncomeMember
2022-12-31
0000792935
us-gaap:RetainedEarningsMember
2022-12-31
0000792935
us-gaap:NoncontrollingInterestMember
2022-12-31
0000792935
us-gaap:SeriesAPreferredStockMember
2022-01-01
2022-12-31
0000792935
us-gaap:CommonStockMember
2022-01-01
2022-12-31
0000792935
us-gaap:AdditionalPaidInCapitalMember
2022-01-01
2022-12-31
0000792935
grst:DiscountToParValueMember
2022-01-01
2022-12-31
0000792935
us-gaap:ComprehensiveIncomeMember
2022-01-01
2022-12-31
0000792935
us-gaap:RetainedEarningsMember
2022-01-01
2022-12-31
0000792935
us-gaap:NoncontrollingInterestMember
2022-01-01
2022-12-31
0000792935
us-gaap:SeriesAPreferredStockMember
2023-01-01
2023-12-31
0000792935
us-gaap:CommonStockMember
2023-01-01
2023-12-31
0000792935
us-gaap:AdditionalPaidInCapitalMember
2023-01-01
2023-12-31
0000792935
grst:DiscountToParValueMember
2023-01-01
2023-12-31
0000792935
us-gaap:ComprehensiveIncomeMember
2023-01-01
2023-12-31
0000792935
us-gaap:RetainedEarningsMember
2023-01-01
2023-12-31
0000792935
us-gaap:NoncontrollingInterestMember
2023-01-01
2023-12-31
0000792935
us-gaap:SeriesAPreferredStockMember
2023-12-31
0000792935
us-gaap:CommonStockMember
2023-12-31
0000792935
us-gaap:AdditionalPaidInCapitalMember
2023-12-31
0000792935
grst:DiscountToParValueMember
2023-12-31
0000792935
us-gaap:ComprehensiveIncomeMember
2023-12-31
0000792935
us-gaap:RetainedEarningsMember
2023-12-31
0000792935
us-gaap:NoncontrollingInterestMember
2023-12-31
0000792935
grst:GreenstoneMuskokaMember
2023-12-31
0000792935
grst:AriaMember
2023-12-31
0000792935
grst:NetBookValueMember
2023-12-31
0000792935
us-gaap:LandMember
2023-12-31
0000792935
us-gaap:LandMember
2022-12-31
0000792935
us-gaap:PropertyPlantAndEquipmentMember
2023-12-31
0000792935
us-gaap:PropertyPlantAndEquipmentMember
2022-12-31
0000792935
us-gaap:LeaseholdImprovementsMember
2023-12-31
0000792935
us-gaap:LeaseholdImprovementsMember
2022-12-31
0000792935
us-gaap:FurnitureAndFixturesMember
2023-12-31
0000792935
us-gaap:FurnitureAndFixturesMember
2022-12-31
0000792935
us-gaap:VehiclesMember
2023-12-31
0000792935
us-gaap:VehiclesMember
2022-12-31
0000792935
us-gaap:ComputerEquipmentMember
2023-12-31
0000792935
us-gaap:ComputerEquipmentMember
2022-12-31
0000792935
grst:LeoniteCapitalLLCMember
2023-01-01
2023-12-31
0000792935
grst:LeoniteCapitalLLCMember
2022-01-01
2022-12-31
0000792935
grst:LeoniteFundILPMember
2023-01-01
2023-12-31
0000792935
grst:LeoniteFundILPMember
2022-01-01
2022-12-31
0000792935
grst:AuctusFundLLCMember
2023-01-01
2023-12-31
0000792935
grst:AuctusFundLLCMember
2022-01-01
2022-12-31
0000792935
grst:LabrysFundLPMember
2023-01-01
2023-12-31
0000792935
grst:LabrysFundLPMember
2022-01-01
2022-12-31
0000792935
grst:EdBlasiakMember
2023-01-01
2023-12-31
0000792935
grst:EdBlasiakMember
2022-01-01
2022-12-31
0000792935
grst:JoshuaBaumanMember
2023-01-01
2023-12-31
0000792935
grst:JoshuaBaumanMember
2022-01-01
2022-12-31
0000792935
grst:ConvertibleNotesMember
2023-01-01
2023-12-31
0000792935
grst:ConvertibleNotesMember
2022-01-01
2022-12-31
0000792935
grst:SeriesNConvertibleNotesMember
2023-01-01
2023-12-31
0000792935
grst:SeriesNConvertibleMember
2023-01-01
2023-12-31
0000792935
grst:SeriesNConvertibleNotesMember
2022-01-01
2022-12-31
0000792935
grst:CranberryCoveHoldingsLtdMember
2023-12-31
0000792935
grst:CranberryCoveHoldingsLtdMember
2022-12-31
0000792935
grst:ShawnEleonMember
2023-01-01
2023-12-31
0000792935
grst:ShawnEleonMember
2022-01-01
2022-12-31
0000792935
grst:LeonDevelopmentsMember
2023-01-01
2023-12-31
0000792935
grst:LeonDevelopmentsMember
2022-01-01
2022-12-31
0000792935
grst:EileenGreeneMember
2023-01-01
2023-12-31
0000792935
grst:EileenGreeneMember
2022-01-01
2022-12-31
0000792935
srt:MinimumMember
2023-01-01
2023-12-31
0000792935
srt:MaximumMember
2023-01-01
2023-12-31
0000792935
grst:Excercise1Member
2023-01-01
2023-12-31
0000792935
grst:Excercise2Member
2023-01-01
2023-12-31
0000792935
grst:Excercise2Member
2023-01-01
2023-12-31
0000792935
grst:RentalOperationsMember
2023-01-01
2023-12-31
0000792935
grst:InPatientsServicesMember
2023-01-01
2023-12-31
0000792935
grst:RentalInPatientServicesMember
2023-01-01
2023-12-31
0000792935
grst:RentalOperationsMember
2023-12-31
0000792935
grst:InPatientServicesMember
2023-12-31
0000792935
grst:RentalInPatientServicesMember
2023-12-31
0000792935
grst:RentalOperationsMember
2022-01-01
2022-12-31
0000792935
grst:InPatientsServicesMember
2022-01-01
2022-12-31
0000792935
grst:RentalInPatientServicesMember
2022-01-01
2022-12-31
0000792935
grst:RentalOperationsMember
2022-12-31
0000792935
grst:InPatientsServicesMember
2022-12-31
0000792935
grst:RentalInPatientServicesMember
2022-12-31
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
xbrli:pure
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 10-K
☒ ANNUAL
REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For
the fiscal year ended: December 31, 2023
or
☐ TRANSITION
REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For
the transition period from ______to _________
Commission
file number: 000-15078
Ethema
Health Corporation
(Exact
name of registrant as specified in its charter)
Colorado 84-1227328
(State
or other jurisdiction of incorporation or organization)
(I.R.S.
Employer Identification No.)
950
Evernia Street
West
Palm Beach, Florida 33401
(Address
of principal executive offices)
(416) 500
0020
(Registrant’s
telephone number, including area code)
Securities registered
under Section 12(b) of the Exchange Act: |
|
Title
of each class |
Name
of each exchange on which registered |
|
|
None |
N/A |
Securities
registered under Section 12(g) of the Act:
Common
Stock, $0.01 par value per share
(Title
of class)
Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒
Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒
Indicate
by check mark whether the issuer: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act
of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has
been subject to such filing requirements for the past 90 days. ☒ Yes No ☐
Indicate
by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every interactive data
file required to be submitted and posted pursuant to Rule 405 of Regulation S-T (section 232.405 of this chapter) during the preceding
12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐
Indicate
by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained,
to the best of issuer’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this
Form 10-K or any amendment to this Form 10-K. ☒
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D.1(b). ☐
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated file, a non-accelerated file, a smaller reporting company,
or an emerging growth company. See the definitions of “large accelerated filer, “accelerated filer,” “smaller
reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer |
☐ |
Accelerated filer |
☐ |
Non-accelerated filer |
☐ (Do not check if a smaller reporting
company) |
Smaller reporting company |
☒ |
|
Emerging growth company |
☐ |
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
The
aggregate market value of the registrant’s common stock held by non-affiliates of the registrant as of June 30, 2023, based on
a closing share price of $0.0006 was approximately $2,073,714.
As
of May 6, 2024, the registrant had 3,729,053,805 shares
of its common stock, par value $0.01 per share, outstanding.
ETHEMA
HEALTH CORPORATION
YEAR
ENDED DECEMBER 31, 2023
TABLE
OF CONTENTS
PART
I
Special
Note Regarding Forward-Looking Statements
Many
of the matters discussed within this Annual Report contain forward-looking statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”) on our current expectations and projections about future events. In
some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “potential,”
“continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,”
“estimates,” and similar expressions. These statements are based on our current beliefs, expectations, and assumptions and
are subject to a number of risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could
cause actual results to differ materially from those expressed, projected or implied in or by the forward-looking statements. Such risks
and uncertainties include the risks noted under Item 7, “Management’s Discussion and Analysis of Financial Condition and
Results of Operations,” but are also contained elsewhere. We do not undertake any obligation to update any forward looking statements.
Unless the context requires otherwise, references to “we,” “us,” “our,” and “Ethema,”
refer to Ethema Health Corporation and its subsidiaries.
Furthermore,
if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in
these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that
we will achieve our objectives and plans in any specified time frame, or at all. We do not undertake any obligation to update any forward-looking
statements.
Item 1. Business.
Company
History
Ethema
Health Corporation (the “Company” or “Ethema”), a Colorado corporation was incorporated under the laws of the
State of Colorado on April 1, 1993, and is the surviving company of a merger, effective February 1, 1995, between the Company and Nova
Natural Resources Corporation, a Delaware corporation (“Nova Delaware”). The merger was effectuated solely for the purpose
of changing the Company’s domicile from Delaware to Colorado. At all times prior to 2001, the Company was engaged in the oil and
gas exploration business. Nova Delaware was the successor entity to Nova Petroleum Corporation, a Delaware corporation, and Power Resources
Corporation, a Delaware corporation, which merged in 1986 (“the 1986 Merger”). Prior to the 1986 Merger, Nova Petroleum Corporation
and Power Resources Corporation had operated since 1979 and 1972, respectively. In 2001, the Company entered into the electronics business
and this business was active in 2001 and 2002, as part of the Torita Group. After 2002, the Company continued with various stages of
development in this business until 2010.
On
April 1, 2010, the Company changed its principal operations from development stage electronics to healthcare services. On March 29, 2010,
the Company entered into a one year consulting agreement with GreeneStone Clinic Inc., a Canadian corporation (“Greenestone Clinic”),
whereby Greenestone Clinic provided consulting services for the Company’s development and operation of medical clinics in the province
of Ontario, Canada. Specifically, Greenestone Clinic provided medical and business expertise in the initial startup of private clinics
and technical assistance to ensure that the clinics were in compliance with governmental policy and procedure requirements as well as
any operational requirements. At the time of entering into this consulting agreement, Greenestone Clinic operated a clinic at the Muskoka
property housing its addiction treatment clinic and provided endoscopy services. The Company started offering medical services in June
2010, offering various medical services, including endoscopy, cardiology and executive medicals, which services were subsequently sold.
During
December 2016, the Company obtained a license to operate and provide addiction treatment healthcare services in Florida, USA. The company
commenced operations under this license with effect from January 2017.
On
February 14, 2017, the Company completed a series of transactions (referred to collectively as the “Restructuring Transactions”),
including a Share Purchase Agreement (the “SPA”) whereby the Company
acquired 100% of the stock of Cranberry Cove Holdings Ltd. (“CCH”) from Leon Developments Ltd. (“Leon Developments”),
a company wholly owned by Shawn E. Leon, who is the President, CEO, and CFO of the Company, for an assignment to Leon Developments of
CDN$659,918 owing to the Company and the issuance of 60,000,000 shares of the Company’s common stock valued at $2,184,000. CCH
held the real estate on which the Company’s GreeneStone Muskoka operated. The Company entered into an Asset Purchase Agreement
(the “APA”) whereby the assets of GreeneStone Muskoka were sold by
GreeneStone Muskoka, to Canadian Addiction Residential Treatment LP (the “Purchaser” or “CART”), for a total
consideration of CDN$10,000,000. The company also entered into a lease agreement whereby the Company leased the real estate to Cart for
an initial 5 year period with three 5 year renewal options.
On
February 14, 2017, immediately after closing on the sale of the assets of GreeneStone Muskoka, the Company closed on the acquisition
of the business and real estate assets of Seastone Delray pursuant to certain real estate and asset purchase agreements through
its wholly owned subsidiary, Addiction Recovery Institute of America, LLC (“ARIA”). The purchase price for the ARIA assets
was US$6,070,000.
On
April 4, 2017 the Company changed its Corporate name from Greenestone Healthcare Corporation to Ethema Health Corporation.
On
November 2, 2017, the Company entered into an Agreement to purchase certain buildings in West Palm Beach, Florida, totaling approximately
80,000 square feet, on which the Company planned to operate a substance abuse treatment center. The purchase price of the Property was
$20,530,000. The Company made a series of nonrefundable down payments totaling $2,940,546 in 2017 and 2018. On May 23, 2018, the Company
converted the agreement to purchase the buildings from the Landlord into a real property lease agreement with a purchase option. The
lease was for an initial 10 years and provided for two additional 10 year extensions. In June 2018, the Company moved its ARIA operations
into the West Palm Beach properties and in September 2018 received a license to operate in-patient detoxification and residential treatment
services. On December 20,2019, the Company entered into an agreement with the landlord to terminate the lease agreement on January 31,
2020.
On April
2, 2019, the Company disposed of the real estate assets in ARIA located at 801 Andrews Avenue, Delray Beach for gross proceeds of $3,500,000,
and on October 10, 2019, the Company transferred the remaining real estate asset located at 810 Andrews Avenue, Delray Beach, Florida
to Leonite Capital, LLC, for net proceeds of $1,398,510, which proceeds were offset against the convertible loan owing to Leonite.
On
June 30, 2020, the Company entered into an agreement (“the Stock Purchase Agreement”), whereby the Company agreed to acquire
51% of American Treatment Holdings, Inc. (“ATHI”) from The Q Global Trust (“Seller”) and Lawrence B Hawkins (“Hawkins”),
which owned 100% of Evernia Health Services LLC. (“Evernia”), which operates drug rehabilitation facilities. The consideration
for the acquisition was a loan to be provided by the Company to Evernia in the amount of $500,000. The Company has an option to acquire
an additional 24% of ATHI for 100,000,000 shares of common stock and $50,000, on the condition that a probationary license was approved
by the Florida Department of Family and Child Services, which was received on June 30,2021, upon which the Company exercised its option
to acquire the additional 24% of ATHI, resulting in a 75% ownership of ATHI.
On
December 30, 2022, the company entered into two agreements whereby it sold two non-operating subsidiaries, Greenstone Muskoka and ARIA
to the Company Chairman and CEO for gross proceeds of $0, after Greenstone Muskoka forgave its intercompany receivable owing from the
Company of $6,690,381 and the Company forgave its intercompany balance owing from ARIA of $9,605,315.
On
June 30, 2023, the Company entered into an exchange agreement with Leonite Capital, LLC, whereby it exchanged 400,000 Series B shares
with a value of $400,000 plus accrued dividends thereon of $61,184 for its entire shareholding in its property owning subsidiary, CCH.
The Series B shares were cancelled upon consummation of the transaction.
On
October 3, 2022 the Company entered into a purchase and sale agreement with Evernia Station Limited Partnership for the purchase of 950
Evernia Street, West Palm Beach, Florida (“950”), the property in which it operates its treatment center, for gross proceeds
of $5,500,000. (“Purchase Agreement”). The closing was originally scheduled for February 1, 2023, however through a series
of 6 addendums to the Purchase Agreement requiring the payment of a total $180,000 in extension fees, the Closing was extended to August
3, 2023.
Simultaneously
with the closing of the purchase and sale agreements, on August 4, 2023, the Company entered into a long term lease for 950 with an initial
term of twenty years, and two ten year extension options. The lessor is Pontus EHC Palm Beach, LLC , a Delaware limited liability company
and a portfolio company of Pontus Net Lease Advisors, LLC. The lease is absolutely net and the lease cost for the initial year is $748,000
paid monthly. The lease increases at a rate of 2.75% per year for a total term lease obligation of $19,595,653 over the initial twenty-year
term.
Corporate
Structure
The
Company consists of the following entities:
|
Ethema Health
Corporation (Parent company); |
Ethema
is the publicly traded investment holding company, registered in Colorado, U.S.
|
American
Treatment Holdings, Inc, a US registered company (75% owned); |
ATHI
owns 100% of the members interest of Evernia.
|
Evernia
Health Center, a US registered company; |
Evernia
operates a treatment center in West Palm Beach Florida and is a wholly owned subsidiary of ATHI which was acquired by Ethema effective
July 1, 2021. The Company has been actively involved in the operation of this treatment center since June 30, 2020.
|
Delray Andrews
RE, LLC (“DARE”), a US registered company (wholly owned and dormant); |
DARE
has remained dormant since inception.
Employees
As
of December 31, 2023, Ethema had 65 employees.
Marketing
The
addiction treatment business in the USA operates as an insured healthcare service. Our marketing efforts are long-term processes of establishing
relationships with relevant professionals and our treatment staff. We use industry
specific conferences and functions to network with these professionals.
Through
Evernia, the Company has an in-network relationship with several health care providers and the majority of the Company’s clients
are sourced from these health care providers.
Competition
There
are a significant amount of treatment facilities in the United States, we compete with these clinics for patients who are typically covered
by insured healthcare services.
Environmental
Regulations
The
Company is not currently subject to any pending administrative or judicial enforcement proceedings arising under environmental laws or
regulations. Environmental laws and regulations may be adopted in the future which may have an impact upon the Company’s operations.
Item
1A. Risk Factors.
Not
applicable because we are a smaller reporting company.
Item
1B. Unresolved Staff Comments
None.
Item
2. Properties.
Ethema
Executive Offices
The
Company’s executive offices are located at 950 Evernia Street, West Palm Beach, Florida, 33406.
West
Palm Beach Treatment Operations
The Company,
through its acquisition of ATHI, effectively acquired 75% of the Evernia treatment facility located at 950 Evernia Street, West Palm
Beach Florida. The Company has been actively involved in the operation of the Evernia treatment facility since June 2020.
Item 3. Legal
Proceedings.
We
are currently not involved in any litigation that we believe could have a material adverse effect on our financial condition or results
of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency,
self-regulatory organization or body pending or, to the knowledge of the executive
officers of our company or any of our subsidiaries, threatened against or affecting our company, our common stock, any of our subsidiaries
or of our companies or our subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could
have a material adverse effect.
Item
4. Mine Safety Disclosures.
None.
PART
II
Item
5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities .
The
Company’s common stock is quoted on the Over-the-counter Market (the “OTC PINK”) under the symbol “GRST”.
The Company was sponsored by the market maker Wilson Davis & Co. from Salt Lake City, Utah,
which filed a Form 15c2-11 application with the Financial Industry Regulatory Authority (“FINRA”) for the Company in 2011.
This application was approved by FINRA in February 2012, and Wilson Davis & Co. first quoted the stock in March 2012.
From
March 2012 to January 2020, our common stock had been traded on the OTCQB markets under the symbol “GRST”, in January 2020,
the stock was downgraded to the OTC Pink Sheets market.
The last reported sale price
of our common stock on the OTC Pink on May 6, 2024 was $0.0003 per share. As of May 6, 2024, there were approximately 157 holders of record
of our common stock.
Dividend
Policy
We
have not paid any cash dividends on our common stock to date, and we have no intention of paying cash dividends in the foreseeable future.
Whether we declare and pay dividends is determined by our Board of Directors at their discretion, subject to certain limitations imposed
under Colorado corporate law. The timing, amount and form of dividends, if any, will depend on, among other things, our results of operations,
financial condition, cash requirements and other factors deemed relevant by our Board of Directors.
Equity
Compensation Plan Information
See
Item 11 - Executive Compensation for equity compensation plan information.
Recent
Sales of Unregistered Securities
Other
than as set forth below or as previously disclosed in our filings with the Securities and Exchange Commission, we did not sell any equity
securities during the year ended December 31, 2023 in transactions that were none registered under the Securities Act.
On June 28, 2023 the Company entered into a Warrant Exchange Agreement with a previous lender that exchanged a Warrant outstanding to
the previous lender originally issued on June 12, 2020 for a new Warrant dated June 30, 2023. The substantial changes to the warrant
affect the number of shares in the warrant, the exercise price and the term. The original warrant provided for the previous lender to
have a continuing right to purchase a 20% share of the outstanding common shares until it expired on June 12, 2025 which was originally
set at 326,286,847 shares. The new warrant is exercisable for 745,810,761 shares, 20% of the number of common shares outstanding on June
28, 2023, with no allowance for adjustment, except normal adjustments due to splits or consolidations, until the new expiry date of June
30, 2027. The exercise price in the original warrant was $0.10, with allowance for adjustments, which when applied resulted in an exercise
price of $0.0004 per share. The exercise price on the new warrant is $0.001 and is only adjustable if the Company issues any shares at
a price less than the exercise price during the warrant period except for any issuance of shares to the Company’s president or
related parties on any debt outstanding to those parties as of June 30, 2023, and limited to a conversion price of $0.0005 per share.
Penny
Stock
The
U.S. Securities and Exchange Commission (the “SEC”) has adopted rules that regulate broker dealer practices in connection
with transactions in penny stocks. Penny stocks are generally equity securities with a market price of less than $5.00, other than securities
registered on certain national securities exchanges or quoted on the NASDAQ system, provided that current price and volume information
with respect to transactions in such securities is provided by the exchange or system. The penny stock rules require a broker dealer,
prior to a transaction in a penny stock, to deliver a standardized risk disclosure document prepared by the SEC, that: (a) contains a
description of the nature and level of risk in the market for penny stocks in both public offerings and secondary trading; (b) contains
a description of the broker’s or dealer’s duties to the customer and of the rights and remedies available to the customer
with respect to a violation of such duties or other requirements of the securities laws. (c) contains a brief, clear, narrative description
of a dealer market, including bid and ask prices for penny stocks and the significance of the spread between the bid and ask price;
(d) contains a toll-free telephone number for inquiries on disciplinary actions; (e) defines significant terms in the disclosure
document or in the conduct of trading in penny stocks; and (f) contains such other information and is in such form, including language,
type size and format, as the SEC shall require by rule or regulation.
The
broker dealer also must provide, prior to effecting any transaction in a penny stock, the customer with (a) bid and offer quotations
for the penny stock; (b) the compensation of the broker dealer and its salesperson in the transaction; (c) the number of shares
to which such bid and ask prices apply, or other comparable information relating to the depth and liquidity of the market for such stock;
and (d) a monthly account statement showing the market value of each penny stock held in the customer’s account.
In
addition, the penny stock rules require that prior to a transaction in a penny stock not otherwise exempt from those rules, the broker
dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser’s
written acknowledgment of the receipt of a risk disclosure statement, a written agreement as to transactions involving penny stocks,
and a signed and dated copy of a written suitability statement.
These
disclosure requirements may have the effect of reducing the trading activity for our common stock. Therefore, stockholders may have difficulty
selling our securities.
Issuer
Purchases of Equity Securities
There
were no issuer purchases of equity securities during the fiscal year ended December 31, 2023.
Item
6. Reserved
Item 7. Management’s
Discussion and Analysis of Financial Condition and Results of Operations.
The
following discussion and analysis should be read in conjunction with, and is qualified in its entirety by, our audited annual financial
statements and the related notes thereto, each of which appear elsewhere in this Annual Report. This discussion contains certain forward-looking
statements that involve risks and uncertainties in this Annual Report. Actual results could differ materially from those projected in
the forward-looking statements. The Management Discussion and Analysis of Financial Condition and Results of Operations below is based
upon only the financial performance of Ethema Health Corporation.
Our
consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”).
These accounting principles require us to make certain estimates, judgments, and assumptions. We believe that the estimates, judgments
and assumptions upon which we rely are reasonable based upon information available to us at the time that these estimates, judgments,
and assumptions are made. These estimates, judgments, and assumptions can affect the reported amounts of assets and liabilities as of
the date of the consolidated financial statements as well as the reported amounts of revenues and expenses during the periods presented.
Our consolidated financial statements would be affected to the extent there are material differences between these estimates. This discussion
and analysis should be read in conjunction with the company’s consolidated financial statements and accompanying notes to the consolidated
financial statements for the year ended December 31, 2023.
Results
of operations for the year ended December 31, 2023 and the year ended December 31, 2022.
Revenue
Revenue
was $5,344,976 and $4,820,747 for the years ended December 31, 2023 and 2022, respectively, an increase of $524,229 or 10.9%.
Revenue
from patient treatment was $5,159,680 and 4,411,546 for the years ended December 31, 2023 and 2022, respectively, an increase of $748,134
or 17.0%. The increase is due to the increase in the number of in-network patients at the facility due to the approval of the facility
by a number of health care plans over the current year.
Revenue
from rental income was $185,296 and $377,351 for the years ended December 31, 2023 and 2022, respectively, a decrease of $192,055 or
50.4%. The Company disposed of its real property owning subsidiary, Cranberry Cove Holdings, to a related party , Leonite Capital, LLC
on June 30, 2023, revenue was only recognized for the first half of the current fiscal year.
Operating
Expenses
Operating expenses was $5,886,896
and $4,331,630 for the years ended December 31, 2023 and 2022, respectively, an increase of $1,555,266 or 35.9%. The increase in operating
expenses is attributable to:
· |
General and administrative expenses was $1,041,501 and $805,372 for the years ended December 31, 2023 and 2022, respectively, an increase of $236,129 or 29.3%. The increase is primarily attributable to due to an increase in insurance costs of $85,701, due to the general hardening of the insurance market in South Florida, an increase in capital raising costs of $40,470 for funds spent on exploring capital raising opportunities, and the balance of $117,959 consisting of increase in numerous individually insignificant costs, related to the increase in the number of patients passing through the facility during the current period. |
· |
Rent expense was $614,793 and $427,482 for the years ended December 31, 2023 and 2022 an increase of $187,311 or 43.8%. The increase is primarily due to an increase in rental which arose on the acquisition of the building from our landlord and the immediate disposal of the building to a third party on August 4, 2023, resulting in the cancellation of the old lease which expired in January 2027 and entering into a new 20 year lease expiring in August 2043, at an increased current rental of $33,161 per month as adjusted for rental smoothing over the term of the lease on both the cancelled old lease and the new 20 year lease, see gain on disposal of property below. |
· |
Management fees were $368,003 and $132,500 for the years ended December 31, 2023 and 2022, respectively, an increase of $235,503 or 177.7%. Management fees included a once off charge of $185,503 related to a fee charged by Leon Developments to Cranberry Cove prior to its disposal to a related party Leonite Capital on June 30, 2023. In addition, the Company paid management fees of $182,500 to the minority shareholder of ATHI during the year. |
|
|
· |
Professional fees were $707,413 and $463,678 for the years ended December 31, 2023 and 2022, respectively, an increase of $243,735 or 52.6%. The increase is primarily due to the increase in professional fees related to the acquisition and immediate disposal of the real property in which the treatment facility operates on August 4, 2023, see gain on disposal of property, below, and an increase in contractor fees related to the increase in the number of patients treated at the facility during the current year, which resulted in increased revenues. |
|
|
· |
Salaries and wages was $2,656,267 and $1,962,479 for the years ended December 31, 2023 and 2022, respectively, an increase of $693,788 or 35.4%. The increase is due to the increase in headcount to service the increase in the number of patients treated at the facility during the current year. |
|
|
· |
Depreciation expense was $498,919 and $540,119 for the years ended December 31, 2023 and 2022, respectively, a decrease of $41,200 or 7.6%. The decrease is primarily due to the disposal of Cranberry Cove Holdings to Leonite Capital, a related party, on June 30, 2023. Cranberry Cove assets included buildings and leasehold improvements which were being depreciated prior to disposal. |
Operating (loss) profit
The operating (loss) profit
was $(541,920) and $489,117 for the years ended December 31, 2023 and 2022, respectively, an increase in loss of $1,031,037 or 210.8%.
The increase in loss is due to the increase in operating expenses of $1,555,266, discussed in detail above, including once off management
fees of $245,503, increased professional fees and capital raising fees which are not expected to incur in future periods, offset by the
increase in revenue of $524,229, discussed in detail above.
Other
income
Other
income was $0 and $15,760 for the years ended December 31, 2023 and 2022, respectively. In 2022 other income consisted of a financial
inducement granted to the Company by the previous landlord.
Forgiveness
of government relief loan
Forgiveness
of government relief loan was $0 and $104,368 for the years ended December 31, 2023 and 2022, respectively, a decrease of $104,368 or
100.0%. The Company received partial forgiveness of the Government assistance loan in the prior
year.
Gain on
disposal of property
Gain on disposal
of property was $2,484,172 and $0 for the year ended December 31, 2023 and 2022, respectively, an increase of $2,484,172 or 100.0%. The
Company exercised its option to acquire the property located at 950 Evernia Street, West Palm Beach, Florida, in which its treatment
center operations, and subsequently disposed of the property to a third party, realizing a profit on disposal of $2,484,172, after transaction
costs.
Loss
on debt extinguishment
Loss
on debt extinguishment was $277,175 and $0 for the years ended December 31, 2023 and 2022, respectively, an increase of $277,175 or 100.0%.
The loss on debt extinguishment is related primarily to replacement warrants issued to Leonite Capital as part of the debt settlement
reached with Leonite.
Extension
fee on property purchase
The
extension fee on the property purchase was $140,000 and $0 for the years ended December 31, 2023 and 2022, respectively, an increase
of $140,000 or 100%. The extension fee was levied by the landlord of our West Palm Beach facility to afford us additional time to structure
the acquisition of the facility, which we in turn disposed of to a third party lender.
Penalty
on convertible debt
The penalty on convertible
notes was $34,688 and $60,075 for the years ended December 31, 2023 and 2022, respectively, an increase of $25,387 or 42.3%. The penalty
on convertible note was agreed upon with one of our lenders whose note was in default and was subsequently settled after June 30, 2023.
Interest
income
Interest
income was $676 and $78 for the years ended December 31, 2023 and 2022 respectively. Interest income is immaterial.
Interest expense
Interest expense was $500,226
and $588,477 for the years ended December 31, 2023 and 2022, respectively, a decrease of $88,251 or 15.0%, primarily due to the decrease
in mortgage interest due to the disposal of CCH, our property owning subsidiary on June 30, 2023, and a decrease in interest expense on
convertible notes and promissory notes settled during the current period.
Debt discount
Debt discount was $281,354
and $624,683 for the years ended December 31, 2023 and 2022, respectively, a decrease of $343,329 or 54.6%. The
decrease is primarily due to the full amortization of debt discount on convertible notes in the prior year. The current year amortization
consists of the amortization of discount on receivables funding.
Foreign exchange movements
Foreign exchange movements
were $(95,032) and $1,071,320 for the years ended December 31, 2023 and 2022, respectively, Foreign exchange movements represents the
realized exchange gains and (losses) on monetary assets and liabilities settled during the current year as well as mark to market unrealized
gains and losses on monetary assets and liabilities reflected on the balance sheet and denominated in Canadian Dollars. In the prior year,
the foreign exchange movements included the realization of significant translation differences on foreign subsidiaries sold and in the
current year we disposed of Cranberry Cove Holdings, our last foreign subsidiary denominated in Canadian Dollars, to a related party.
Net income before taxation
Net income before taxation
was $614,453 and $407,408 for the years ended December 31, 2023 and 2022, respectively, an increase of $207,045 or 50.8%. The
increase is primarily due to the gain on sale of property, and the decrease in debt discount and interest expense, offset by the increase
in the operating loss, the loss on debt extinguishment, the extension fee paid on the property purchase and the foreign exchange movements,
all discussed in detail above.
Taxation
Taxation was $391,962 and
$(112,220) for the years ended December 31, 2023 and 2022, respectively an increase of $504,182 or 449.3%. The
increase is due to the completion of tax returns for our operating subsidiaries during the current year, which resulted in the reversal
of previously provided for income taxes, primarily related to accelerated depreciation allowances on property and equipment and the reversal
of the deferred tax liability related to intangible assets. The 2022 charge relates to the profitable Evernia operations, which
has been subsequently reversed in the 2023 year.
Net income
Net income was $1,006,415
and $295,188 for the years ended December 31, 2023 and 2022, respectively, an increase of $711,227 or 240.9%. The increase is due to the
increase in income before taxation and the reversal of prior period taxation charges and deferred tax balances, discussed above.
Liquidity
and Capital Resources
Cash
used in operating activities was $(0.5) million and cash generated by operating activities was $1.6 million for the
years ended December 31, 2023 and 2022, respectively a decrease of $2.1 million or 129.6%. The decrease is primarily due to the following:
· |
The increase in
net income of $0.7 million, as discussed above; |
|
|
· |
The decrease in non-cash movements of $(2.7) million, primarily due to the gain on disposal of property of $(2.5) million, as discussed above; |
|
|
· |
The increase in working capital of $(0.1) million, primarily due to an increase in the movement of accounts receivable of $0.3 million, a decrease in the movement in accounts payable and accrued liabilities of $(0.1) million, and a decrease in the movement of taxes payable of $0.4 million due to the reversal of prior year tax provisions. |
Cash
provided by investing activities was $2.5 million and cash used in investing activities was $0.7 million for the years ended December
31, 2023 and 2022, respectively. The Company exercised its option to acquire 950 Evernia Street, where it conducts its treatment facility
for net proceeds of $5.2 million, net of $0.4 million of deposits previously paid. Upon acquisition, we immediately
sold the property for net proceeds of $8.1 million, after fees and expenses related to the disposal. During the current year, we paid
a lease deposit of $374,000 for the real property lease entered into immediately upon disposal of the real property. In the prior year
we invested $0.4 million in deposits for the purchase of the Evernia Street property and a further $0.3 million in property and equipment
for the treatment center.
Cash
used in financing activities was $(2.1) million and cash provided by investing activities was $0.3 million for the years ended December
31, 2023 and 2022, respectively. In the current year, the Company used a portion of the proceeds from investing activities for the net
repayment of convertible notes of $(1.0) million, the net repayment of promissory notes of $(0.1) million and the payment of third party
loans of $0.3 million.. The Company also repaid net receivables funding of $0.4 million, mortgage loans of $0.1 million and related party
loans of $0.2 million during the current year. In the prior year, we repaid net promissory notes of $0.1 million, mortgage loans of $0.1
million, and third party loans of $0.1 million, funded by net receivables funding of $$.4 million and related party loans of $0.3 million.
Over
the next twelve months we estimate that the company will require approximately $4.8 million in funding to repay its obligations if these
obligations are not converted to equity. We will need funding for working capital as we continue to seek opportunities for addiction treatment
in the US markets. There is no assurance that the Company will be successful with future financing ventures, and the inability to secure
such financing may have a material adverse effect on the Company’s financial condition. In the opinion of management, the Company’s
liquidity risk is assessed as high.
Going Concern
Our
consolidated financial statements have been prepared in accordance with US GAAP applicable to a going concern, which assumes that we will
be able to meet our obligations and continue our operations in the normal course of business. At December 31, 2023, we had a working capital
deficiency of $7.9 million, and total liabilities in excess of assets in the amount of $6.2 million. We believe that current
available resources will not be sufficient to fund our planned expenditures over the next 12 months. Accordingly, we will be dependent
upon the raising of additional capital through placement of common shares, and/or debt financing in order to implement our business plan
and generate sufficient revenue in excess of costs. If we raise additional capital through the issuance of equity securities or securities
convertible into equity, stockholders will experience dilution, and such securities may have rights, preferences or privileges senior
to those of the holders of common stock or convertible senior notes. If we raise additional funds by issuing debt, we may be subject to
limitations on its operations, through debt covenants or other restrictions. If we obtain additional funds through arrangements with collaborators
or strategic partners, we may be required to relinquish our rights to certain geographical areas, or techniques that it might otherwise
seek to retain. There is no assurance that we will be successful with future financing ventures, and the inability to secure such financing
may have a material adverse effect on our financial condition. These consolidated financial statements do not include any adjustments
to the amounts and classifications of assets and liabilities that might be necessary should we be unable to continue as a going concern.
Critical accounting policies
Revenue
recognition
We
recognize revenue in terms of ASC 606 which requires us to exercise more judgment and recognize revenue using a five-step process as described
under our accounting policies in note 2 to the consolidated financial statements.
We
derive substantially all of our revenue from payors that receive discounts from established billing rates. The various managed care contracts
under which these discounts must be calculated are complex, subject to interpretation and adjustment, and may include multiple reimbursement
mechanisms for different types of services provided in the Company’s inpatient facilities and cost settlement provisions. Management
estimates the transaction price on a payor-specific basis given its interpretation of the applicable regulations or contract terms. The
services authorized and provided and related reimbursement are often subject to interpretation that could result in payments that differ
from the Company’s estimates. Additionally, updated regulations and contract renegotiations occur frequently, necessitating regular
review and assessment of the estimation process by management.
Settlements
with third-party payors are estimated and recorded in the period in which the related services are rendered and are adjusted in future
periods as final settlements are determined. In the opinion of management, adequate provision has been made for any adjustments and final
settlements.
Allowance
for Doubtful Accounts, Contractual and Other Discounts
In conjunction
with Revenue recognition, we recognize revenue based on historical collections received from healthcare providers, recognizing only a
percentage of revenues actually billed. Effectively recognizing revenue net of any expected billing differentials. Based on our collection
experience, the percentage of revenue recognized is adjusted on a periodic basis, thereby taking into account expected credit losses in
the revenue recognition process. The revenue we recognize is already net of expected credit losses.
Leases
We account for leases in terms of ASC 842. In terms
of ASC 842, the Company assesses whether any asset based leases entered into for periods longer than twelve months meet the definition
of financial leases or operation leases, by evaluating the terms of the lease, including the following; the duration of the lease; the
implied interest rate in the lease; the cash flows of the lease; and whether the Company intends to retain ownership of the asset at the
end of the lease term.
Leases which imply that we will not acquire the asset
at the end of the lease term are classified as operating leases, our right to use the asset is reflected as a non-current right of use
asset with a corresponding operational lease liability raised at the date of lease inception. The right of use asset and the operational
lease liability are amortized over the right of use period using the effective interest rate implied in the operating lease agreement.
Long Lived Assets
The Company evaluates the carrying value of its long-lived
assets for impairment by comparing the expected undiscounted future cash flows of the assets to the net book value of the assets when
events or circumstances indicate that the carrying amount of a long-lived asset may not be recoverable. If the expected undiscounted future
cash flows are less than the net book value of the assets, the excess of the net book value over the estimated fair value will be charged
to earnings.
Fair value is based upon discounted cash flows of
the assets at a rate deemed reasonable for the type of asset and prevailing market conditions, appraisals, and, if appropriate, current
estimated net sales proceeds from pending offers.
Critical Accounting Estimates
Preparation of our consolidated financial statements
in accordance with U.S. generally accepted accounting principles (“GAAP”) requires us to make estimates and assumptions that
affect the reported amounts of certain assets, liabilities, revenues and expenses, as well as related disclosure of contingent assets
and liabilities. Our estimates are based on our historical experience, information received from third parties and on various other factors
that we believe are reasonable under the circumstances, that results of which form the basis for making judgments about the carrying value
of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimated under different
assumption or conditions. Significant accounting policies are fundamental to understanding our financial condition and results as they
require the use of estimates and assumptions which affect the financial statements and accompanying notes. See Note 2 - Summary of Significant
Accounting Policies of the Notes to the Consolidated Financial Statements included in Part II, Item 8 of this Annual Report for further
information.
The Critical accounting policies that involved significant
estimation include the following:
Revenue recognition
Management constantly monitors the level of billings
and collections on those billings and makes an estimation of the percentage of billings that will ultimately be recorded as revenue. The
various managed care contracts under which these discounts must be calculated are complex, subject to interpretation and adjustment, and
may include multiple reimbursement mechanisms for different types of services provided in the Company’s inpatient facilities and
cost settlement provisions. Management estimates the transaction price on a payor-specific basis given its interpretation of the applicable
regulations or contract terms. The services authorized and provided and related reimbursement are often subject to interpretation that
could result in payments that differ from the Company’s estimates.
Since we already make adjustments for expected collections
we are constantly taking into account any expected credit losses.
Leases
On August 4, 2023, we entered into
an acquisition and immediate disposal transaction with two unrelated third parties for the building which we currently operate our West
Palm Beach treatment facility, see note 5 to the consolidated financial statements.
Simultaneously
with the acquisition and disposal, on August 4, 2023, we entered into a long term lease for 950 Evernia Street, West Palm Beach, Florida
with an initial term of twenty years, and two ten year extension options. The lease is absolutely net and the lease cost for the initial
year is $748,000 paid monthly. The lease increases at a rate of 2.75% per year for a total term lease obligation of $19,595,653 over the
initial twenty-year term. Due to the initial lease term of twenty years, we are not certain that the extension periods will be exercised
at this point in time and accordingly, these have been excluded from the present value of the minimum future lease payments.
To determine the present
value of minimum future lease payments for operating leases at August 4, 2023, we were required to estimate a rate of interest that we
would have to pay to borrow on a collateralized basis over a similar term in a similar economic environment (the "incremental borrowing
rate" or "IBR"). Wey determined the appropriate IBR by identifying a reference rate and making adjustments that take into
consideration financing options and certain lease-specific circumstances. For the reference rate, the Company used the Fannie Mae, in
excess of $3,000,000 rate based on an 80% value to loan ratio, averaging the 15 and 30 year indicative rates, resulting in a rate of 7.70%.
We determined that 7.70% per annum was an appropriate incremental borrowing rate to apply to its real-estate operating lease.
The present value of the
future minimum lease payments was valued at $9,333,953 on August 4, 2023.
Long-lived assets
We have significant long-lived assets, including property
and equipment, intangible assets, right-of-use assets and deposits. The Company evaluates the carrying value of its long-lived assets
for impairment by comparing managements estimates of undiscounted future cash flows of the assets to the net book value of the assets
when events or circumstances indicate that the carrying amount of a long-lived asset may not be recoverable. This requires significant
estimation of future revenue streams, based on management’s understanding of the business which may not be accurate and may require
re-estimation at a future date. If the expected undiscounted future cash flows are less than the net book value of the assets, the excess
of the net book value over the estimated fair value will be charged to earnings.
Fair value is based upon discounted cash flows of
the assets at a rate deemed by management to be reasonable for the type of asset and prevailing market conditions, appraisals, and, if
appropriate, current estimated net sales proceeds from pending offers.
Item
8. Financial Statements and Supplementary Data.
ETHEMA
HEALTH CORPORATION
INDEX
TO THE CONSOLIDATED FINANCIAL STATEMENTS
(Expressed
in US$ unless otherwise indicated)
REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To
the Board of Directors and Stockholders of
Ethema
Health Corporation and Subsidiaries
West
Palm Beach, FL 33401
Opinion
on the Financial Statements
We
have audited the accompanying consolidated balance sheet of Ethema Health Corporation and Subsidiaries (collectively, the “Company”)
as of December 31, 2023, the related consolidated statement of operations, stockholders’ deficit and cash flows for each of the
year ended December 31, 2023, and the related notes and schedules (collectively referred to as the “financial statements”).
In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December
31, 2023, and the results of its operations and its cash flows for each of the year ended December 31, 2023 in conformity with accounting
principles generally accepted in the United States of America.
The
Company's Ability to Continue as a Going Concern
The
accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. As discussed
in Note 3 to the accompanying consolidated financial statements, the Company has suffered recurring losses from operations, generated
negative cash flows from operating activities, has an accumulated deficit and has stated that substantial doubt exists about Company’s
ability to continue as a going concern. Management's evaluation of the events and conditions and management’s plans in regarding
these matters are also described in Note 3. The consolidated financial statements do not include any adjustments that might result from
the outcome of this uncertainty.
Basis
for Opinion
These
financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits,
we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion
on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.
Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion.
Critical
Audit Matters
The
critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated
or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial
statements and (2) involved our especially challenging, subjective or complex judgments.
We
determined that there are no critical audit matters.
/s/
RBSM LLP
587
We
have served as the Company’s auditor since 2023.
New
York, NY
May
7, 2024
New
York, NY Washington DC Mumbai & Pune, India Boca Raton, FL
San
Francisco, CA Las Vegas, NV Beijing, China Athens, Greece
Member:
ANTEA International with affiliated offices worldwide
REPORT OF INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM
To
the Board of Directors and
Stockholders of Ethema Health Corporation
West
Palm Beach, Florida
Opinion
on the Consolidated Financial Statements
We
have audited the accompanying consolidated balance sheets of Ethema Health Corporation (the Company) at December 31, 2022, and the related
consolidated statements of operations and comprehensive income (loss), changes in stockholders’ deficit, and cash flows for each
of the year ended December 31, 2022, and the related notes (collectively referred to as the consolidated financial statements). In our
opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December
31, 2022, and the results of its operations and its cash flows for the year ended December 31, 2022, in conformity with accounting principles
generally accepted in the United States of America.
Basis
for Opinion
The
accompanying consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express
an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with
the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company
in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission
and the PCAOB.
We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.
The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part
of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing
an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.
Our
audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether
due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles
used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.
We believe that our audits provide a reasonable basis for our opinion.
Going
Concern
The accompanying consolidated
financial statements have been prepared assuming that the Company will continue as a going concern. As described in Note 3 to the consolidated
financial statements, the Company has accumulated deficit of approximately $43.5 million and negative working capital of approximately
$12.7 million at December 31, 2022, which raises substantial doubt about its ability to continue as a going concern. Management’s
plans in regard to these matters are described in Note 3. The consolidated financial statements do not include any adjustments that might
result from the outcome of this uncertainty.
Critical Audit Matters
The critical audit matters
communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or
required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated
financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit
matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating
the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which
they relate.
Accounting for Embedded Conversion
Features on Convertible Notes – Refer to Notes 9 and 14 to the Financial Statements
The principal considerations
for our determination that performing procedures relating to the valuation of derivatives is a critical audit matter are the significant
judgment by management when developing the fair value of the derivative liabilities. This in turn led to a high degree of auditor judgment,
subjectivity, and effort in performing procedures and evaluating management’s significant assumptions related to the valuation models
used and related variable inputs used within those models.
Addressing
the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated
financial statements. These procedures included testing management’s process for developing the fair value estimate; evaluating
the appropriateness of the valuation techniques; testing the completeness and accuracy of underlying data used in the model; and evaluating
the significant assumptions used by management, including the values of expected volatility and discount rate. Evaluating management’s
assumptions related to the volatility amounts and discount rates involved evaluating whether the assumptions used by management were
reasonable considering the current and historical performance, the consistency with external market and industry data, and whether these
assumptions were consistent with evidence obtained in other areas of the audit.
/s/ Daszkal
Bolton LLP |
|
|
|
|
Boca
Raton, Florida |
|
|
March
31, 2023 |
|
|
|
We
served as the Company’s auditor from 2018 to March 2023. |
|
ETHEMA
HEALTH CORPORATION
CONSOLIDATED
BALANCE SHEETS
| |
December
31, 2023 | |
December
31, 2022 |
ASSETS | |
|
| |
| |
|
Current
assets | |
| | | |
| | |
Cash | |
$ | 68,573 | | |
$ | 140,757 | |
Accounts
receivable, net | |
| 313,338 | | |
| 337,074 | |
Prepaid
expenses | |
| 18,159 | | |
| 44,718 | |
Other
current assets | |
| 3,030 | | |
| 20,347 | |
Total
current assets | |
| 403,100 | | |
| 542,896 | |
Non-current
assets | |
| | | |
| | |
Property
and equipment | |
| 508,401 | | |
| 2,974,395 | |
Intangible
assets, net | |
| 894,952 | | |
| 1,252,932 | |
Right
of use assets | |
| 9,323,723 | | |
| 1,393,071 | |
Deposits
paid | |
| 389,000 | | |
| 400,000 | |
Total
non-current assets | |
| 11,116,076 | | |
| 6,020,398 | |
Total
assets | |
$ | 11,519,176 | | |
$ | 6,563,294 | |
| |
| | | |
| | |
LIABILITIES
AND STOCKHOLDERS’ DEFICIT | |
| | | |
| | |
| |
| | | |
| | |
Current
liabilities | |
| | | |
| | |
Accounts
payable and accrued liabilities | |
$ | 352,101 | | |
$ | 170,934 | |
Taxes
payable | |
| — | | |
| 248,644 | |
Convertible
notes, net of discounts | |
| 4,419,927 | | |
| 5,269,250 | |
Short-term
notes | |
| 680,672 | | |
| 460,534 | |
Mortgage
loans | |
| — | | |
| 3,504,605 | |
Receivables
funding | |
| 211,961 | | |
| 416,731 | |
Government
assistance loans | |
| 14,962 | | |
| 14,818 | |
Operating
lease liability | |
| 38,563 | | |
| 287,017 | |
Finance
lease liability | |
| 8,426 | | |
| 7,891 | |
Accrued
dividends | |
| — | | |
| 194,829 | |
Related
party payables | |
| 2,572,292 | | |
| 2,713,878 | |
Total
current liabilities | |
| 8,298,904 | | |
| 13,289,131 | |
Non-current
liabilities | |
| | | |
| | |
Government
assistance loans | |
| 20,520 | | |
| 79,555 | |
Deferred
taxation | |
| — | | |
| 217,451 | |
Third
party loans | |
| — | | |
| 578,335 | |
Operating
lease liability | |
| 9,383,557 | | |
| 1,206,413 | |
Finance
lease liability | |
| 16,475 | | |
| 24,952 | |
Total
non-current liabilities | |
| 9,420,552 | | |
| 2,106,706 | |
Total
liabilities | |
| 17,719,456 | | |
| 15,395,837 | |
| |
| | | |
| | |
Preferred
stock - Series B; $1.00 par
value 10,000,000
authorized, 0 and 400,000 shares
issued and outstanding as of December 31, 2023 and 2022, respectively. | |
| — | | |
| 400,000 | |
| |
| | | |
| | |
Stockholders’
deficit | |
| | | |
| | |
Preferred
stock - Series A; $0.01 par
value, 10,000,000 authorized,
4,000,000 shares
issued and outstanding as of December 31, 2023 and 2022. | |
| 40,000 | | |
| 40,000 | |
Common stock - $0.01 par
value, 10,000,000,000 shares
authorized; 3,729,053,805 shares
issued and outstanding as of December 31, 2023 and December 31, 2022. | |
| 37,290,539 | | |
| 37,290,539 | |
Additional
paid-in capital | |
| 26,187,925 | | |
| 23,419,917 | |
Discount for shares issued
below par value | |
| (27,363,367 | ) | |
| (27,363,367 | ) |
Accumulated
other comprehensive loss | |
| — | | |
| (5,065 | ) |
Accumulated
deficit | |
| (42,355,377 | ) | |
| (43,484,751 | ) |
Stockholders’
deficit attributable to Ethema Health Corporation stockholders’ | |
| (6,200,280 | ) | |
| (10,102,727 | ) |
Non-controlling
interest | |
| — | | |
| 870,184 | |
Total
stockholders’ deficit | |
| (6,200,280 | ) | |
| (9,232,543 | ) |
Total
liabilities and stockholders’ deficit | |
$ | 11,519,176 | | |
$ | 6,563,294 | |
The
accompanying notes are an integral part of the consolidated financial statements
ETHEMA
HEALTH CORPORATION
CONSOLIDATED
STATEMENTS OF OPERATIONS
AND
COMPREHENSIVE (LOSS) INCOME
| |
Year
ended December 31, 2023 | |
Year
ended December 31, 2022 |
| |
| |
|
Revenues | |
$ | 5,344,976 | | |
$ | 4,820,747 | |
| |
| | | |
| | |
Operating expenses | |
| | | |
| | |
General and administrative | |
| 1,041,501 | | |
| 805,372 | |
Rent expense | |
| 614,793 | | |
| 427,482 | |
Management fees | |
| 368,003 | | |
| 132,500 | |
Professional fees | |
| 707,413 | | |
| 463,678 | |
Salaries and wages | |
| 2,656,267 | | |
| 1,962,479 | |
Depreciation
expense | |
| 498,919 | | |
| 540,119 | |
Total
operating expenses | |
| 5,886,896 | | |
| 4,331,630 | |
| |
| | | |
| | |
Operating (loss) profit | |
| (541,920 | ) | |
| 489,117 | |
| |
| | | |
| | |
Other (expense) income | |
| | | |
| | |
Other income | |
| — | | |
| 15,760 | |
Forgiveness of government
relief loan | |
| — | | |
| 104,368 | |
Gain on sale of
property | |
| 2,484,172 | | |
| — | |
Loss on debt extinguishment | |
| (277,175 | ) | |
| — | |
Extension fee on property
purchase | |
| (140,000 | ) | |
| — | |
Penalty on notes and convertible
notes | |
| (34,688 | ) | |
| (60,075 | ) |
Interest income | |
| 676 | | |
| 78 | |
Interest expense | |
| (500,226 | ) | |
| (588,477 | ) |
Debt discount | |
| (281,354 | ) | |
| (624,683 | ) |
Foreign
exchange movements | |
| (95,032 | ) | |
| 1,071,320 | |
Taxation | |
| 391,962 | | |
| (112,220 | ) |
Net income | |
| 1,006,415 | | |
| 295,188 | |
Net loss (income) attributable
to non-controlling interest | |
| 170,184 | | |
| (47,308 | ) |
Net income attributable
to Ethema Health Corporation Stockholders’ | |
| 1,176,599 | | |
| 247,880 | |
Preferred stock dividend | |
| (47,225 | ) | |
| (97,782 | ) |
Net income available to
common shareholders of Ethema Health Corporation | |
| 1,129,374 | | |
| 150,098 | |
Accumulated other comprehensive
loss | |
| | | |
| | |
Foreign
currency translation adjustment | |
| — | | |
| (821,597 | ) |
| |
| | | |
| | |
Total
comprehensive income (loss) | |
$ | 1,129,374 | | |
$ | (671,499 | ) |
| |
| | | |
| | |
Basic income per common share | |
$ | 0.00 | | |
$ | 0.00 | |
Diluted income per common share | |
$ | 0.00 | | |
$ | 0.00 | |
Weighted average common shares outstanding
– Basic | |
| 3,729,053,805 | | |
| 3,704,807,230 | |
Weighted average common shares outstanding
– Diluted | |
| 3,903,671,684 | | |
| 4,276,363,181 | |
The
accompanying notes are an integral part of the consolidated financial statements
ETHEMA
HEALTH CORPORATION
CONSOLIDATED
STATEMENTS OF STOCKHOLDERS’ DEFICIT
| |
|
|
|
| |
|
|
|
| |
| |
| |
| |
| |
| |
|
| |
Series A Preferred | |
Common | |
Additional
Paid | |
Discount | |
Comprehensive | |
Accumulated | |
Non- controlling
shareholders | |
|
| |
Shares | |
Amount | |
Shares | |
Amount | |
in Capital | |
to par value | |
Income | |
Deficit | |
Interest | |
Total |
Balance as of December
31, 2021 | |
| 4,000,000 | | |
| 40,000 | | |
| 3,579,053,805 | | |
| 35,790,539 | | |
| 22,791,350 | | |
| (26,013,367 | ) | |
| 816,532 | | |
| (44,103,311 | ) | |
| 822,876 | | |
| (9,855,381 | ) |
Adjustments to prior period on adoption of
ASU 2020-06 | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| 468,462 | | |
| — | | |
| 468,462 | |
Conversion of convertible notes | |
| — | | |
| — | | |
| 150,000,000 | | |
| 1,500,000 | | |
| — | | |
| (1,350,000 | ) | |
| — | | |
| — | | |
| — | | |
| 150,000 | |
Transactions with related parties | |
| — | | |
| — | | |
| — | | |
| — | | |
| 628,567 | | |
| — | | |
| — | | |
| — | | |
| — | | |
| 628,567 | |
Foreign currency translation | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| (821,597 | ) | |
| — | | |
| — | | |
| (821,597 | ) |
Net income | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| | | |
| — | | |
| 247,880 | | |
| 47,308 | | |
| 295,188 | |
Dividends accrued | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| (97,782 | ) | |
| — | | |
| (97,782 | ) |
Balance as of December 31, 2022 | |
| 4,000,000 | | |
$ | 40,000 | | |
| 3,729,053,805 | | |
$ | 37,290,539 | | |
$ | 23,419,917 | | |
$ | (27,363,367 | ) | |
$ | (5,065 | ) | |
$ | (43,484,751 | ) | |
$ | 870,184 | | |
$ | (9,232,543 | ) |
Disposal of subsidiary to related party | |
| — | | |
| — | | |
| — | | |
| — | | |
| 2,034,885 | | |
| — | | |
| — | | |
| — | | |
| (700,000 | ) | |
| 1,334,885 | |
Deemed extinguishment of debt by related party | |
| — | | |
| — | | |
| — | | |
| — | | |
| 461,184 | | |
| — | | |
| — | | |
| — | | |
| — | | |
| 461,184 | |
Fair value of warrants issued on debt extinguishment | |
| — | | |
| — | | |
| — | | |
| — | | |
| 271,939 | | |
| — | | |
| — | | |
| — | | |
| — | | |
| 271,939 | |
Foreign currency translation | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| 5,065 | | |
| — | | |
| — | | |
| 5,065 | |
Net income | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| 1,176,599 | | |
| (170,184 | ) | |
| 1,006,415 | |
Dividends accrued | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| (47,225 | ) | |
| — | | |
| (47,225 | ) |
Balance as of December 31, 2023 | |
| 4,000,000 | | |
$ | 40,000 | | |
| 3,729,053,805 | | |
$ | 37,290,539 | | |
$ | 26,187,925 | | |
$ | (27,363,367 | ) | |
| — | | |
| (42,355,377 | ) | |
| — | | |
| (6,200,280 | ) |
The
accompanying notes are an integral part of the consolidated financial statement
ETHEMA
HEALTH CORPORATION
CONSOLIDATED
STATEMENTS OF CASH FLOWS
| |
Year
ended December
31, 2023 | |
Year
ended December
31, 2022 |
Operating
activities | |
| | | |
| | |
Net
income | |
$ | 1,006,415 | | |
$ | 295,188 | |
Adjustment
to reconcile net income to net cash (used in) provided by operating activities: | |
| | | |
| | |
Depreciation
and amortization expense | |
| 498,919 | | |
| 540,119 | |
Amortization
of debt discount | |
| 281,354 | | |
| 624,683 | |
Gain
on disposal of property | |
| (2,484,172 | ) | |
| — | |
Loss
on debt extinguishment | |
| 277,175 | | |
| — | |
Forgiveness
of federal relief loan | |
| — | | |
| (104,368 | ) |
Penalty
on promissory notes | |
| 34,688 | | |
| 60,075 | |
Amortization
of right of use asset | |
| 177,220 | | |
| 260,745 | |
Deferred
taxation movement | |
| (217,451 | ) | |
| (55,606 | ) |
Changes
in operating assets and liabilities | |
| | | |
| | |
Accounts
receivable | |
| 78,037 | | |
| (215,364 | ) |
Prepaid
expenses | |
| 26,562 | | |
| (14,996 | ) |
Other
current assets | |
| 5,513 | | |
| (3,113 | ) |
Accounts
payable and accrued liabilities | |
| 201,978 | | |
| 305,785 | |
Operating
lease liabilities | |
| (179,184 | ) | |
| (241,083 | ) |
Taxes
payable | |
| (237,211 | ) | |
| 125,014 | |
Net
cash (used in) provided by operating activities | |
| (530,157 | ) | |
| 1,577,079 | |
| |
| | | |
| | |
Investing
activities | |
| | | |
| | |
Acquisition
of real property, net of $400,000 deposit paid | |
| (5,209,276 | ) | |
| — | |
Proceeds
on disposal of real property | |
| 8,093,448 | | |
| — | |
Purchase
of property and equipment | |
| (40,602 | ) | |
| (315,822 | ) |
Proceeds
on sale of subsidiary, net of cash of $1,421 | |
| — | | |
| (1,421 | ) |
Proceeds
from deposits | |
| — | | |
| 4,984 | |
Investment
in deposits | |
| (389,000 | ) | |
| (400,000 | ) |
Net
cash provided by (used in) investing activities | |
| 2,454,570 | | |
| (712,259 | ) |
| |
| | | |
| | |
Financing
activities | |
| | | |
| | |
Repayment of mortgage | |
| (58,320 | ) | |
| (117,073 | ) |
Proceeds
from convertible notes | |
| 150,000 | | |
| — | |
Repayment
of convertible notes | |
| (1,153,666 | ) | |
| — | |
Proceeds
from promissory notes | |
| 447,000 | | |
| 160,000 | |
Repayment
of promissory notes | |
| (568,325 | ) | |
| (289,044 | ) |
Proceeds
from receivables funding | |
| 580,646 | | |
| 682,500 | |
Repayment
of receivables funding | |
| (994,483 | ) | |
| (330,312 | ) |
Repayment
of government assistance loans | |
| (14,579 | ) | |
| (2,970 | ) |
Repayment
of third party loans | |
| (283,746 | ) | |
| (76,856 | ) |
Repayment
of finance leases | |
| (7,943 | ) | |
| (7,437 | ) |
(Repayment) proceeds
of related party notes | |
| (174,012 | ) | |
| 284,906 | |
Net
cash (used in ) provided by financing activities | |
| (2,077,428 | ) | |
| 303,714 | |
| |
| | | |
| | |
Effect
of exchange rate on cash | |
| 80,831 | | |
| (1,076,599 | ) |
| |
| | | |
| | |
Net
change in cash | |
| (72,184 | ) | |
| 91,935 | |
Beginning
cash balance | |
| 140,757 | | |
| 48,822 | |
Ending
cash balance | |
$ | 68,573 | | |
$ | 140,757 | |
| |
| | | |
| | |
Supplemental
cash flow information | |
| | | |
| | |
Cash
paid for interest | |
$ | 425,117 | | |
$ | 234,240 | |
Cash
paid for income taxes | |
$ | — | | |
$ | — | |
| |
| | | |
| | |
Non-cash
investing and financing activities | |
| | | |
| | |
Fair
value of warrant issued on debt extinguishment | |
$ | 271,939 | | |
$ | — | |
Disposal
of subsidiary to related party | |
$ | 1,334,885 | | |
$ | — | |
Deemed
extinguishment of debt by related party | |
$ | 461,184 | | |
$ | — | |
Conversion
of convertible notes | |
$ | — | | |
$ | 150,000 | |
The
accompanying notes are an integral part of the consolidated financial statements
ETHEMA
HEALTH CORPORATION
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
1. Nature
of business
Since
2010, the Company has operated addiction treatment centers. Initially the Company operated an addiction treatment center in Ontario Canada
under its Greenestone Muskoka clinic, which was sold on February 14, 2017. Simultaneously with this sale the Company purchased buildings
and operated an addiction treatment center in Delray Beach Florida under its Addiction recovery Institute of America subsidiary with
a license obtained in December 2016, initially though owned properties in Delray Beach and subsequently though leased properties in West
Palm Beach, Florida. Since June 30, 2020, the Company has been actively involved in the management of a treatment center operated by
Evernia in West Palm Beach Florida. On July 1, 2021, the Company closed on the acquisition of 75% of ATHI, which owns 100% of Evernia,
once the probationary approval of a license was obtained from the Department of Children and Family Services of Florida. Evernia is currently
the only active treatment center operated by the Company.
The
Company sold its real estate on which its Greenstone Muskoka clinic operated during the current year, see note 4 below.
2. Summary
of significant accounting policies
Financial
Reporting
The
Company prepares its consolidated financial statements in conformity with accounting principles generally accepted in the United States
of America (“US GAAP”).
Management
further acknowledges that it is solely responsible for adopting sound accounting practices, establishing and maintaining a system of
internal accounting control and preventing and detecting fraud. The Company’s system of internal accounting control is designed
to assure, among other items, that i) recorded transactions are valid; ii) valid transactions are recorded; and iii) transactions are
recorded in the proper period in a timely manner to produce financial statements which present fairly the financial condition, results
of operations and cash flows of the Company for the respective periods being presented.
a)
Use of Estimates
The
preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated
financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from
those estimates.
b) Principals
of consolidation and foreign currency translation
The
accompanying consolidated financial statements include the accounts of the Company and all of its subsidiaries. All intercompany transactions
and balances have been eliminated on consolidation.
Certain
of the Company’s previous subsidiaries functional currency was the Canadian dollar, while the Company’s reporting currency
is the U.S. dollar. All transactions initiated in Canadian dollars are translated into US dollars in accordance with ASC 830, “Foreign
Currency Translation” as follows:
|
● |
Monetary
assets and liabilities at the rate of exchange in effect at the balance sheet date. |
|
● |
Certain
non-monetary assets and liabilities and equity at historical rates. |
|
● |
Revenue
and expense items and cash flows at the average rate of exchange prevailing during the year. |
Adjustments
arising from such translations were deferred until realization and were included as a separate component of stockholders’ deficit
as a component of accumulated other comprehensive income or loss. Therefore, translation adjustments were not included in determining
net income (loss) but reported as other comprehensive income (loss).
For
foreign currency transactions, the Company translates these amounts to the Company’s functional currency at the exchange rate effective
on the invoice date. If the exchange rate changes between the time of purchase and the time actual payment is made, a foreign exchange
transaction gain or loss results which is included in determining net income for the year.
The
relevant translation rates are as follows: For the year ended December 31, 2023, a closing rate of CDN$1 equals US$0.7561 and an average
exchange rate of CDN$1 equals US$0.7409, for the year ended December 31, 2022, a closing rate of CDN$1.0000 equals US$0.7383 and an average
exchange rate of CDN$1.0000 equals US$0.7686.
ETHEMA
HEALTH CORPORATION
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
2. Summary
of significant accounting policies (continued)
c)
Business Combinations
The
Company allocates the fair value of purchase consideration to the tangible and intangible assets acquired and liabilities assumed for
business combinations with third parties based on their estimated fair values. The excess of the fair value of purchase consideration
over the fair values of these identifiable assets and liabilities is recorded as goodwill.
Such
valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Significant
estimates in valuing certain intangible assets include, but are not limited to, future expected cash flows from acquired users, acquired
technology, and trade names from a market participant perspective, useful lives and discount rates. Management's estimates of fair value
are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results
may differ from estimates.
d)
Cash and cash equivalents
For
purposes of the statements of cash flows, the Company considers all highly liquid instruments purchased with a maturity of three months
or less and money market accounts to be cash equivalents. The Company maintains cash and cash equivalents with several financial institution
in the USA and Canada. There were no cash equivalents at December 31, 2023 and 2022.
The
Company primarily places cash balances in the USA with high-credit quality financial institutions located in the United States which
are insured by the Federal Deposit Insurance Corporation up to a limit of $250,000
per institution.
e)
Accounts receivable
Accounts
receivable primarily consists of amounts due from third-party payors (non-governmental) and private pay patients and is recorded net
of allowances for doubtful accounts and contractual discounts. The Company’s ability to collect outstanding receivables is critical
to its results of operations and cash flows. Accordingly, accounts receivable reported in the Company’s consolidated financial
statements is recorded at the net amount expected to be received. The Company’s primary collection risks are (i) the risk
of overestimating net revenues at the time of billing that may result in the Company receiving less than the recorded receivable, (ii) the
risk of non-payment as a result of commercial insurance companies denying claims, (iii) the risk that patients will fail to remit
insurance payments to the Company when the commercial insurance company pays out-of-network claims directly to the patient, (iv) resource
and capacity constraints that may prevent the Company from handling the volume of billing and collection issues in a timely manner, (v) the
risk that patients do not pay the Company for their self-pay balances (including co-pays, deductibles and any portion of the claim not
covered by insurance) and (vi) the risk of non-payment from uninsured patients.
f)
Allowance for Doubtful Accounts, Contractual and Other Discounts
The
Company derives the majority of its revenues from commercial payors at in-network rates. The Company recognizes revenue based on historical
collections received from healthcare providers, recognizing only a percentage of revenues actually billed. Effectively recognizing revenue
net of any expected billing differentials. Based on the Company’s collection experience, the percentage of revenue recognized is
adjusted on a periodic basis, thereby taking into account expected credit losses in the revenue recognition process. The revenue we recognize
is already net of expected credit losses, therefore management does not maintain a separate allowance for doubtful accounts, contractual
and other discounts.
Management
also takes into consideration the age of accounts, creditworthiness and current economic trends when evaluating the percentage of revenue
to be recognized.
g) Leases
The Company accounts for leases in terms
of ASC 842. In terms of ASC 842, the Company assesses whether any asset based leases entered into for periods longer than twelve months
meet the definition of financial leases or operation leases, by evaluating the terms of the lease, including the following; the duration
of the lease; the implied interest rate in the lease; the cash flows of the lease; and whether the Company intends to retain ownership
of the asset at the end of the lease term.
Leases which imply that the Company will
retain ownership at the end of the lease term are classified as financial leases, are included in property and equipment with a corresponding
financial liability raised at the date of lease inception. Interest incurred on financial leases are expensed using the effective interest
rate method.
Leases which imply that the Company will
not acquire the asset at the end of the lease term are classified as operating leases, the Company’s right to use the asset is reflected
as a non-current right of use asset with a corresponding operational lease liability raised at the date of lease inception. The right
of use asset and the operational lease liability are amortized over the right of use period using the effective interest rate implied
in the operating lease agreement.
h)
Property and equipment
Property
and equipment is recorded at cost. Depreciation is calculated on the straight line basis over the estimated life of the asset.
ETHEMA
HEALTH CORPORATION
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
2. Summary
of significant accounting policies (continued)
i) Long Lived Assets
The Company evaluates the carrying value
of its long-lived assets for impairment by comparing the expected undiscounted future cash flows of the assets to the net book value of
the assets when events or circumstances indicate that the carrying amount of a long-lived asset may not be recoverable. If the expected
undiscounted future cash flows are less than the net book value of the assets, the excess of the net book value over the estimated fair
value will be charged to earnings.
Fair value is based upon discounted cash
flows of the assets at a rate deemed reasonable for the type of asset and prevailing market conditions, appraisals, and, if appropriate,
current estimated net sales proceeds from pending offers.
j)
Intangible assets
Intangible
assets are stated at acquisition cost less accumulated amortization, if applicable, less any adjustments for impairment losses.
Amortization
is charged on a straight-line basis over the estimated remaining useful lives of the individual intangibles. Where intangibles are deemed
to be impaired the Company recognizes an impairment loss measured as the difference between the estimated fair value of the intangible
and its book value.
Licenses
to provide substance abuse rehabilitation services are amortized over the expected life of the contract, including any anticipated renewals.
The Company expects its licenses to remain in operation for a period of five years.
k) Leases
The
Company accounts for leases in terms of AC 842 whereby leases are classified as either finance or operating leases. Leases that transfer
substantially all of the benefits and inherent risks of ownership of property to the Company are accounted for as finance leases. At
the time a finance lease is entered into, an asset is recorded together with its related long-term obligation to reflect the acquisition
and financing. Property and equipment recorded under finance leases is amortized on the same basis as described above. Operating leases
are recognized on the balance sheet as a lease liability with a corresponding right of use asset for all leases with a term that is more
than twelve months. Payments under operating leases are expensed as incurred.
l)
Derivatives
The
Company evaluates embedded conversion features within convertible debt under ASC 815 “Derivatives and Hedging” to determine
whether the embedded conversion feature should be bifurcated from the host instrument and accounted for as a derivative at fair value
with changes in fair value recorded in earnings. The Company previously used a Black Scholes Option Pricing model to estimate the fair
value of convertible debt conversion features at the end of each applicable reporting period. Changes in the fair value of these derivatives
during each reporting period were included in the statements of operations. Inputs into the Black Scholes Option Pricing model require
estimates, including such items as estimated volatility of the Company’s stock, risk free interest rate and the estimated life
of the financial instruments being fair valued.
If
the conversion feature does not require derivative treatment under ASC 815, the instrument is evaluated under ASC 470-20 “Debt
with Conversion and Other Options” for consideration of any beneficial conversion feature.
m)
Financial instruments
The
Company initially measures its financial assets and liabilities at fair value, except for certain non-arm’s length transactions.
The Company subsequently measures all its financial assets and financial liabilities at amortized cost.
Financial
assets measured at amortized cost include cash and accounts receivable.
Financial
liabilities measured at amortized cost include bank indebtedness, accounts payable and accrued liabilities, withholding taxes payable,
convertible notes payable, loans payable and related party notes.
Financial
assets measured at cost are tested for impairment when there are indicators of impairment. The amount of the write-down is recognized
in net income. The previously recognized impairment loss may be reversed to the extent of the improvement, directly or by adjusting the
allowance account, provided it is no greater than the amount that would have been reported at the date of the reversal had the impairment
not been recognized previously. The amount of the reversal is recognized in net income. The Company recognizes its transaction costs
in net income in the period incurred. However, financial instruments that will not be subsequently measured at fair value are adjusted
by the transaction costs that are directly attributable to their origination, issuance or assumption.
FASB
ASC 820 defines fair value, establishes a framework for measuring fair value in accordance with generally accepted accounting principles,
and expands disclosures about fair value measurements. ASC 820 establishes a three tier fair value hierarchy, which prioritizes the inputs
used in measuring fair value as follows:
|
● |
Level
1. Observable inputs such as quoted prices in active markets; |
|
● |
Level
2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and |
|
● |
Level
3. Unobservable inputs in which there is little or no market data, which requires the reporting entity to develop its own assumptions. |
The
Company measures its convertible debt and any derivative liabilities associated therewith at fair value. These liabilities are revalued
periodically and the resultant gain or loss is realized through the consolidated Statement of Operations and Comprehensive Loss.
ETHEMA
HEALTH CORPORATION
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
2. Summary
of significant accounting policies (continued)
n) Related
parties
Parties
are considered to be related to the Company if the parties directly or indirectly, through one or more intermediaries, control, are controlled
by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members
of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if
one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting
parties might be prevented from fully pursuing its own separate interests. The Company discloses all related party transactions. All
transactions are recorded at fair value of the goods or services exchanged.
o) Revenue
recognition
ASC
606 requires companies to exercise more judgment and recognize revenue using a five-step process.
The
Company’s provision for doubtful accounts are recorded as a direct reduction to revenue instead of being presented as a separate
line item on the consolidated statements of operations and comprehensive loss.
As
our performance obligations relate to contracts with a duration of one year or less, the Company elected the optional exemption in ASC
606-10-50-14(a). Therefore, the Company is not required to disclose the transaction price for the remaining performance obligations at
the end of the reporting period or when the Company expects to recognize the revenue. The Company has minimal unsatisfied performance
obligations at the end of the reporting period as our patients typically are under no obligation to remain admitted in our facilities.
The
Company receives payments from the following sources for services rendered in our U.S. Facility: (i) commercial insurers; and (ii) individual
patients and clients. As the period between the time of service and time of payment is typically one year or less, the Company elected
the practical expedient under ASC 606-10-32-18 and does not adjust for the effects of a significant financing component.
The
Company derives a significant portion of its revenue from payors that receive discounts from established billing rates. The various managed
care contracts under which these discounts must be calculated are complex, subject to interpretation and adjustment, and may include
multiple reimbursement mechanisms for different types of services provided in the Company’s inpatient facilities and cost settlement
provisions. Management estimates the transaction price on a payor-specific basis given its interpretation of the applicable regulations
or contract terms. The services authorized and provided and related reimbursement are often subject to interpretation that could result
in payments that differ from the Company’s estimates. Additionally, updated regulations and contract renegotiations occur frequently,
necessitating regular review and assessment of the estimation process by management.
Settlements
with third-party payors are estimated and recorded in the period in which the related services are rendered and are adjusted in future
periods as final settlements are determined. In the opinion of management, adequate provision has been made for any adjustments and final
settlements. However, there can be no assurance that any such adjustments and final settlements will not have a material effect on the
Company’s financial condition or results of operations. The Company’s receivables were $313,338 and $337,074 at
December 31, 2023 and December 31, 2022, respectively. Management believes that these receivables are properly stated and are not likely
to be settled for a significantly different amount.
The
Company’s revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that
reflects the consideration that the Company expects to receive in exchange for those services. The Company derives its revenues from
the sale of its services. The Company applies the following five steps in order to determine the appropriate amount of revenue to
be recognized as it fulfills its obligations under each of its revenue transactions:
|
i. |
identify the contract with a customer; |
|
ii. |
identify the performance obligations in the contract; |
|
iii. |
determine the transaction price; |
|
iv. |
allocate the transaction price to performance obligations
in the contract; and |
|
v. |
recognize revenue as the performance
obligation is satisfied. |
ETHEMA
HEALTH CORPORATION
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
2. Summary
of significant accounting policies (continued)
p)
Income taxes
The
Company accounts for income taxes under the provisions of ASC Topic 740, “Income Taxes”. Under ASC Topic
740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated
financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income taxes are provided
using the liability method. Under this method, deferred income taxes are recognized for the tax consequences of temporary differences
by applying enacted statutory rates applicable to future years to differences between the financial statement carrying amounts and the
tax bases of existing assets and liabilities. The tax basis of an asset or liability is the amount attributed to that asset or liability
for tax purposes. The effect on deferred taxes of a change in tax rates is recognized in income in the period of change. A valuation
allowance is provided to reduce the amount of deferred tax assets if it is considered more likely than not that some portion of, or all
of, the deferred tax assets will not be realized.
ASC Topic
740 contains a two-step approach to recognizing and measuring uncertain tax positions taken or expected to be taken in a tax return.
The first step is to determine if the weight of available evidence indicates that it is more likely than not that the tax position will
be sustained in an audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax
benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. The Company recognizes interest and
penalties accrued on unrecognized tax benefits within general and administrative expense. To the extent that accrued interest and penalties
do not ultimately become payable, amounts accrued will be reduced and reflected as a reduction in general and administrative expenses
in the period that such determination is made. The tax returns for fiscal 2019, through 2021 are subject to audit or review by the US
tax authorities, whereas fiscal 2011 through 2021 are subject to audit or review by the Canadian tax authority.
q)
Net income per Share
Basic
net income per share is computed on the basis of the weighted average number of common stock outstanding during the year.
Diluted
net income per share is computed on the basis of the weighted average number of common stock and common stock equivalents outstanding.
Dilutive securities having an anti-dilutive effect on diluted net income per share are excluded from the calculation.
Dilution
is computed by applying the treasury stock method for options and warrants. Under this method, “in-the money” options and
warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained
thereby were used to purchase common stock at the average market price during the period. Dilution is computed by applying the if-converted
method for convertible preferred stocks. Under this method, convertible preferred stock is assumed to be converted at the beginning of
the period (or at the time of issuance, if later), and preferred dividends (if any) will be added back to determine income applicable
to common stock. The shares issuable upon conversion will be added to weighted average number of common stock outstanding. Conversion
will be assumed only if it reduces earnings per share (or increases loss per share).
r)
Stock based compensation
Stock
based compensation cost is measured at the grant date, based on the estimated fair value of the award and is recognized as expense over
the employee’s requisite service period or vesting period on a straight-line basis. Share-based compensation expense recognized
in the consolidated statements of operations for the year ended December 31, 2023 and 2022 is based on awards ultimately expected to
vest and has been reduced for estimated forfeitures. This estimate will be revised in subsequent periods if actual forfeitures differ
from those estimates. We have no awards with performance conditions and no awards dependent on market conditions.
ETHEMA
HEALTH CORPORATION
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
2. Summary
of significant accounting policies (continued)
s)
Financial instruments Risks
The
Company is exposed to various risks through its financial instruments. The following analysis provides a measure of the Company’s
risk exposure and concentrations at the balance sheet date, December 31, 2023 and 2022.
Credit
risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an
obligation. Financial instruments that subject the Company to credit risk consist primarily of accounts receivable.
Credit
risk associated with accounts receivable is mitigated as only a percentage of the revenue billed to health insurance companies is recognized
as income until such time as the actual funds are collected. The revenue is concentrated amongst several health insurance companies located
in the US.
In
the opinion of management, credit risk with respect to accounts receivable is assessed as low.
Liquidity
risk is the risk the Company will not be able to meet its financial obligations as they fall due. The Company is exposed to liquidity
risk through its working capital deficiency of approximately $7.9 million, and an accumulated deficit of approximately $42.4 million.
The Company is dependent upon the raising of additional capital in order to implement its business plan. There is no assurance that the
Company will be successful with future financing ventures, and the inability to secure such financing may have a material adverse effect
on the Company’s financial condition. In the opinion of management, liquidity risk is assessed as high, material and remains unchanged
from that of the prior year.
Market
risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices.
Market risk comprises of three types of risk: interest rate risk, currency risk, and other price risk. The Company is exposed to interest
rate risk and currency risk.
Interest
rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market
interest rates. The Company is exposed to interest rate risk on its convertible debt, short term loans, third party loans and government
assistance loans as of December 31, 2023. In the opinion of management, interest rate risk is assessed as moderate.
Currency
risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange
rates. The Company has limited exposure to assets and liabilities denominated in foreign currencies. The Company has not entered into
any hedging agreements to mitigate this risk. In the opinion of management, currency risk is assessed as low, material and remains unchanged
from that of the prior year.
Other
price risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market
prices (other than those arising from interest rate risk or currency risk), whether those changes are caused by factors specific to the
individual financial instrument or its issuer, or factors affecting all similar financial instruments traded in the market. In the opinion
of management, the Company is not exposed to this risk and remains unchanged from the prior year.
t) Recent
accounting pronouncements
The
Financial Accounting Standards Board (“FASB”) issued additional updates during the year ended December 31, 2023. None of
these standards are either applicable to the Company or require adoption at a future date and none are expected to have a material impact
on the Company’s consolidated financial statements upon adoption.
ETHEMA
HEALTH CORPORATION
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
3.
Going concern
The
Company’s consolidated financial statements have been prepared in accordance with US GAAP applicable to a going concern, which
assumes that the Company will be able to meet its obligations and continue its operations in the normal course of business. At December
31, 2023, the Company has a working capital deficiency of $7.4 million, and total liabilities in excess of assets in the amount
of $6.2 million . Management believes that current available resources will not be sufficient to fund the Company’s planned
expenditures over the next 12 months. Accordingly, the Company will be dependent upon the raising of additional capital through placement
of common shares, and/or debt financing in order to implement its business plan and generating sufficient revenue in excess of costs.
If the Company raises additional capital through the issuance of equity securities or securities convertible into equity, stockholders
will experience dilution, and such securities may have rights, preferences or privileges senior to those of the holders of common stock
or convertible senior notes. If the Company raises additional funds by issuing debt, the Company may be subject to limitations on its
operations, through debt covenants or other restrictions. If the Company obtains additional funds through arrangements with collaborators
or strategic partners, the Company may be required to relinquish its rights to certain geographical areas, or techniques that it might
otherwise seek to retain. There is no assurance that the Company will be successful with future financing ventures, and the inability
to secure such financing may have a material adverse effect on the Company’s financial condition. These consolidated financial
statements do not include any adjustments to the amounts and classifications of assets and liabilities that might be necessary should
the Company be unable to continue as a going concern.
4.
Disposal of subsidiaries
On
June 30, 2023, the Company entered into an exchange agreement with Leonite Capital, LLC, whereby it exchanged the 400,000 Series B shares
with a value of $400,000 plus accrued dividends thereon of $61,184 for its entire shareholding in its property owning subsidiary, Cranberry
Cove Holdings. The Series B shares were cancelled upon consummation of the transaction.
Immediately
prior to the disposal of Cranberry Cove Holdings, the Company assumed the loan owed to a third party of $779,005 and the loan owing to
Leon Developments of $1,973,837, Leon developments, a related party, owned by the Company’s CEO, Shawn Leon. In addition, the Company
forgave the intercompany debt owing by Cranberry Cove Holdings of $4,566,848.
The
assets and liabilities disposed of were as follows:
Schedule
of assets and liabilities Disposal
| |
Net
book value |
Assets | |
| | |
Other receivable | |
$ | 12,015 | |
Property
and equipment | |
| 2,420,499 | |
| |
| 2,432,514 | |
Liabilities | |
| | |
Accounts payable and accrued
liabilities | |
| (196,859 | ) |
Government assistance loans | |
| (45,317 | ) |
Mortgage
loan | |
| (3,525,223 | ) |
| |
| (3,767,399 | ) |
| |
| | |
Disposal of subsidiary
to related party – recorded as additional paid in capital | |
$ | (1,334,885 | ) |
The
minority shareholders interest related to the Series A preferred stock in Cranberry Cove Holdings was recorded as a deemed contribution
to the Company and credited to additional paid in capital, resulting in a total credit to additional paid in capital of $2,034,885.
The
cancellation of the Series B shares, which were owned by Leonite Capital, a related party, was deemed to be an extinguishment of debt
by a related party and recorded as a credit to additional paid in capital of $461,184.
ETHEMA
HEALTH CORPORATION
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
| 4. | Disposal
of subsidiaries (continued) |
On
December 30, 2022, the Company entered into two agreements whereby it sold Greenstone Muskoka and ARIA to the Company Chairman and CEO
for gross proceeds of $0.
Immediately
prior to the disposal of these subsidiaries, Greenstone Muskoka forgave its intercompany receivable owing from the Company of $6,690,381
and the Company forgave its intercompany balance owing from ARIA of $9,605,315.
The
Company also assumed the liability to pay for the Government assistance loan of $50,073.
Disposal
Groups including discontinued operations
The
assets and liabilities disposed of were as follows:
| |
Greenstone
Muskoka | |
ARIA | |
Net
book value |
Assets | |
| | | |
| | | |
| | |
Cash | |
$ | 382 | | |
$ | 1,038 | | |
$ | 1,420 | |
| |
| 382 | | |
| 1,038 | | |
| 1,420 | |
| |
| | | |
| | | |
| | |
Liabilities | |
| | | |
| | | |
| | |
Accounts payable and accrued
liabilities | |
| — | | |
| 134,795 | | |
| 134,795 | |
Payroll taxes | |
| 134,812 | | |
| — | | |
| 134,812 | |
Income
taxes payable | |
| 360,380 | | |
| — | | |
| 360,380 | |
| |
| 495,192 | | |
| 134,795 | | |
| 629,987 | |
| |
| | | |
| | | |
| | |
Net liabilities sold | |
| 494,810 | | |
| 133,757 | | |
| 628,567 | |
Net proceeds realized | |
| — | | |
| — | | |
| — | |
Gain
on disposal booked as adjustment to paid in capital | |
$ | 494,810 | | |
$ | 133,757 | | |
$ | 628,567 | |
5.
Property and equipment
Acquisition
and simultaneous disposition of property
On
October 3, 2022 the Company entered into a purchase and sale agreement with Evernia Station Limited Partnership for the purchase of 950
Evernia Street, West Palm Beach, Florida (“950”), the property in which it operates its treatment center, for gross proceeds
of $5,500,000. (“Purchase Agreement”). The closing was originally scheduled for February 1, 2023, however through a series
of 6 addendums to the Purchase Agreement requiring the payment of a total $180,000 in extension fees, the Closing was extended to August
3, 2023.
On
February 27, 2023 the Company signed a listing agreement with Stream Capital Partners listing 950 for sale at a price of $9,568,000 with
the intention of identifying a buyer that would purchase and then potentially enter into a lease agreement with the Company.
On
May 4, 2023 the Company signed a Letter of Intent with Pontus Net Lease Advisers, LLC to sell 950 for $8,500,000 and lease the property
to the Company for a term of twenty years with two ten year extensions. On May 19, 2023, the Company signed a purchase and sale agreement
with Pontus Net Lease Advisors to sell 950 for $8,500,000. On August 4, 2023, the Company completed both the purchase of 950 from Evernia
Station Limited Partnership and the subsequent sale of 950 to Pontus Net Lease Advisors, LLC.
Simultaneously
with the closing of the purchase and sale agreements, on August 4, 2023, the Company entered into a long term lease for 950 with an initial
term of twenty years, and two ten year extension options. The lessor is Pontus EHC Palm Beach, LLC , a Delaware limited liability company
and a portfolio company of Pontus Net Lease Advisors, LLC. The lease is absolutely net and the lease cost for the initial year is $748,000
paid monthly. The lease increases at a rate of 2.75% per year for a total term lease obligation of $19,595,653 over the initial twenty-year
term. The Lease is personally guaranteed by the Company President and the guarantee may be released after 5 years based on certain financial
and performance metrics being met.
The
Company paid gross proceeds of $1,449,000 to Leonite Capital and Leonite Fund I, LP in settlement of all amounts outstanding to both entities,
disclosed in notes 9 and 10 below. In addition, $65,450 was paid to Ed Blasiak to settle the convertible promissory note disclosed in
note 9 below, $179,474 was paid to Joshua Bauman to settle the convertible promissory note disclosed in note 9 below, and $260,548 was
paid to Mirage Realty, LLC to settle the senior secured promissory note, disclosed in note 10 below.
ETHEMA
HEALTH CORPORATION
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
| 5. | Property
and equipment (continued) |
Acquisition
and simultaneous disposition of property (Continued)
The
details of the property purchase and subsequent sale are as follows:
Property
purchase and subsequent sale
| |
Amount |
Purchase of 950 Evernia
Street property | |
| | |
Purchase price | |
$ | 5,500,000 | |
Fees
and expenses related to property purchase | |
| 109,276 | |
Total acquisition cost | |
| 5,609,276 | |
| |
| | |
Proceeds on sale | |
| 8,500,000 | |
Fees
and expenses related to disposal of the property | |
| (406,552 | ) |
Net proceeds on
disposal of property | |
| 8,093,448 | |
| |
| | |
Gain
on sale of property | |
$ | 2,484,172 | |
Property
and equipment consists of the following:
Schedule
of sale of property
| |
December
31, 2023 | |
December
31, 2022 |
| |
Cost | |
Accumulated
depreciation | |
Net
book value | |
Net
book value |
Land | |
$ | — | | |
$ | — | | |
$ | — | | |
$ | 158,742 | |
Property | |
| — | | |
| — | | |
| — | | |
| 2,310,448 | |
Leasehold improvements | |
| 459,439 | | |
| (88,131 | ) | |
| 371,308 | | |
| 373,320 | |
Furniture and fittings | |
| 152,234 | | |
| (47,519 | ) | |
| 104,715 | | |
| 92,941 | |
Vehicles | |
| 55,949 | | |
| (29,060 | ) | |
| 26,889 | | |
| 38,079 | |
Computer equipment | |
| 7,525 | | |
| (2,036 | ) | |
| 5,489 | | |
| 865 | |
| |
$ | 675,147 | | |
$ | (166,746 | ) | |
$ | 508,401 | | |
$ | 2,974,395 | |
Depreciation
expense for the year ended December 31, 2023 and 2022 was $140,939 and
$182,139,
respectively.
6. Intangibles
Intangible
assets consist of the Company’s estimate of the fair value of intangibles acquired with the acquisition of ATHI. The Company allocated
the excess over the tangible assets acquired, less the liabilities assumed to the contract provided to the Company by a health care service
provider.
Intangible
assets consist of the following:
Schedule
of Intangible assets
| |
|
|
|
|
|
|
|
|
|
| |
|
| |
December
31, 2023 | |
December
31, 2022 |
| |
Cost | |
Accumulated
amortization | |
Net
book value | |
Net
book value |
Health care
Provider license | |
$ | 1,789,903 | | |
$ | (894,951 | ) | |
$ | 894,952 | | |
$ | 125,293 | |
| |
| | | |
| | | |
| | | |
| | |
The
Company evaluates intangible assets for impairment on an annual basis during the last month of each year and at an interim date if indications
of impairment exist. Intangible asset impairment is determined by comparing the fair value of the asset to its carrying amount with an
impairment being recognized only when the fair value is less than carrying value and the impairment is deemed to be permanent in nature.
The
Company recorded $357,981 in
amortization expense for finite-lived assets for the years ended December 31, 2023 and 2022.
Estimated
future amortization expense is as follows:
Estimated
future amortization expense
|
|
|
|
Amount |
|
2024 |
|
|
$ |
357,981 |
|
2025 |
|
|
|
357,981 |
|
2026 |
|
|
|
178,990 |
|
Total estimated amortization expense |
|
|
$ |
894,952 |
|
ETHEMA
HEALTH CORPORATION
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
7.
Leases
The
Company acquired ATHI on July 1, 2021, ATHI’s wholly owned subsidiary had entered into an operating lease agreement for certain
real property located at 950 Evernia Street, West
Palm Beach, Florida, with effect from February 1, 2019 for a period of three years, expiring on 1 February 2022. Under the terms
of the lease agreement, the lease was extended during October 2021 for a further 5 year period until 1 February 2027.
As
described in note 5 above, on October 3, 2022 the Company entered into a purchase and sale agreement with Evernia Station Limited Partnership
for the purchase of 950 Evernia Street, West Palm Beach, Florida, the property in which it operates its treatment center, for gross proceeds
of $5,500,000. On August 3, 2023, after 6 addendums to the agreement, the Company closed on the acquisition of the property. This resulted
in the termination of the lease with Evernia station, resulting in the reversal of the remaining right-of-use asset of $1,226,080 and
the associated operating lease liability of $1,328,803, which liability included $102,723 of accrued rental, which was offset against
the rental expense.
On
August 4, 2023, the Company entered into a long term lease for 950 Evernia Street, West Palm Beach, Florida with an initial term of twenty
years, and two ten year extension options. The lessor is Pontus EHC Palm Beach, LLC , a Delaware limited liability company and a portfolio
company of Pontus Net Lease Advisors, LLC. The lease is absolutely net and the lease cost for the initial year is $748,000 paid monthly.
The lease increases at a rate of 2.75% per year for a total term lease obligation of $19,595,653 over the initial twenty-year term. The
Lease is personally guaranteed by the Company President and the guarantee may be released after 5 years based on certain financial and
performance metrics being met. Due to the initial lease term of twenty years, the Company is not certain that the extension periods will
be exercised at this point in time and accordingly, these have been excluded from the present value of the minimum future lease payments.
To
determine the present value of minimum future lease payments for operating leases at August 4, 2023, the Company was required to estimate
a rate of interest that we would have to pay to borrow on a collateralized basis over a similar term in a similar economic environment
(the "incremental borrowing rate" or "IBR").
The
Company determined the appropriate IBR by identifying a reference rate and making adjustments that take into consideration financing
options and certain lease-specific circumstances. For the reference rate, the Company used the Fannie Mae, in excess of $3,000,000 rate
based on an 80% value to loan ratio, averaging the 15 and 30 year indicative rates, resulting in a rate of 7.70%. The Company determined
that 7.70% per annum was an appropriate incremental borrowing rate to apply to its real-estate operating lease.
The
present value of the future minimum lease payments was valued at $9,333,953 on August 4, 2023.
Right of use assets are included in the consolidated balance sheet are as follows:
Schedule
of Right of use assets
| |
December
31, 2023 | |
December
31, 2022 |
Non-current assets | |
| | | |
| | |
Right-of-use
assets – finance leases, net of depreciation, included in Property and equipment | |
$ | 24,901 | | |
$ | 38,079 | |
Right-of-use assets
- operating leases, net of amortization | |
$ | 9,323,723 | | |
$ | 1,393,071 | |
Lease
costs consists of the following:
Schedule
of lease cost
| |
|
|
|
|
|
|
| |
Year ended
December 31, |
| |
2023 | |
2022 |
Finance lease cost: | |
| | | |
| | |
Amortization of right-of-use assets | |
$ | 11,190 | | |
$ | 11,190 | |
Interest expense on finance
lease liabilities | |
| 1,938 | | |
| 2,443 | |
| |
| 13,128 | | |
| 13,633 | |
| |
| | | |
| | |
Operating
lease cost | |
$ | 598,336 | | |
$ | 400,207 | |
Lease
cost | |
$ | 611,464 | | |
$ | 413,840 | |
Other
lease information:
Schedule
of Other lease
| |
|
|
|
|
|
|
| |
Year ended
December 31, |
| |
2023 | |
2022 |
Cash paid for amounts included in the measurement
of lease liabilities | |
| |
|
Operating cash flows from finance
leases | |
$ | (1,938 | ) | |
$ | (2,443 | ) |
Operating cash flows from operating leases | |
| (600,299 | ) | |
| (380,545 | ) |
Financing cash flows from
finance leases | |
| (7,891 | ) | |
| (7,437 | ) |
Cash
paid for amounts included in the measurement of lease liabilities | |
$ | (610,127 | ) | |
$ | (390,425 | ) |
| |
| | | |
| | |
Weighted average lease term – finance
leases | |
| 2
years and ten months | | |
| 3
years and ten months | |
Weighted average remaining lease term –
operating leases | |
| 19
years and 8 months | | |
| 4
years and 1 months | |
| |
| | | |
| | |
Discount rate – finance leases | |
| 6.60 | % | |
| 6.60 | % |
Discount rate – operating leases | |
| 7.7 | % | |
| 4.64 | % |
ETHEMA
HEALTH CORPORATION
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
Maturity
of Leases
Finance
lease liability
The
amount of future minimum lease payments under finance leases as of December 31, 2023 is as follows:
Schedule
of Finance lease liability
|
|
Amount |
2024 |
|
$ |
9,829 |
|
2025 |
|
|
9,829 |
|
2026 |
|
|
6,195 |
|
2027 |
|
|
1,707 |
|
|
|
|
27,560 |
|
Imputed interest |
|
|
(2,659) |
|
Total finance lease liability |
|
$ |
24,901 |
|
Disclosed as: |
|
|
|
|
Current portion |
|
$ |
8,426 |
|
Non-Current portion |
|
|
16,475 |
|
Lease liability |
|
$ |
24,901 |
|
Operating
lease liability
The
amount of future minimum lease payments under operating leases are as follows:
Schedule
of Operating lease liability
|
|
Amount |
|
|
|
2023 |
|
$ |
754,857 |
|
2024 |
|
|
775,615 |
|
2025 |
|
|
796,945 |
|
2026 |
|
|
818,861 |
|
2027 and thereafter |
|
|
16,200,042 |
|
Total undiscounted minimum future lease payments |
|
|
19,346,320 |
|
Imputed interest |
|
|
(9,924,200 |
) |
Total operating lease liability |
|
$ |
9,422,120 |
|
|
|
|
|
|
Disclosed as: |
|
|
|
|
Current portion |
|
$ |
38,563 |
|
Non-Current portion |
|
|
9,383,557 |
|
Lease liability |
|
$ |
9,422,120 |
|
8.
Taxes Payable
Taxes
payable consist of:
Schedule
of taxation payable
| |
December
31, 2023 | |
December
31, 2022 |
| |
| |
|
HST/GST payable | |
| — | | |
| 74,134 | |
Income tax payable | |
| — | | |
| 174,510 | |
| |
$ | — | | |
$ | 248,644 | |
On
June 30, 2023, the Company entered into an exchange agreement with Leonite Capital, LLC, whereby it exchanged the 400,000 Series B shares
with a value of $400,000 plus accrued dividends thereon of $61,184 for its entire shareholding in its property owning subsidiary, Cranberry
Cove Holdings. The HST/GST payable was settled prior to disposal.
The
income tax provision raised in previous years was reversed in the current year upon filing the tax returns with no taxation payable.
ETHEMA
HEALTH CORPORATION
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
9. Short-term
Convertible Notes
The
short-term convertible notes consist of the following:
Schedule
of short-term convertible notes
|
|
Interest
rate |
|
Maturity
Date |
|
Principal |
|
Interest |
|
December
31, 2023 |
|
December
31, 2022 |
Leonite Capital, LLC |
|
|
12.0 |
% |
|
On
Demand |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
184,749 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Leonite Fund I, LP |
|
|
Variable |
|
|
March
1, 2023 |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
720,830 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Auctus Fund, LLC |
|
|
0.0 |
% |
|
On
Demand |
|
|
70,000 |
|
|
|
— |
|
|
|
70,000 |
|
|
|
80,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Labrys Fund, LP |
|
|
12.0 |
% |
|
On
Demand |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
8,826 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ed Blasiak |
|
|
6.5 |
% |
|
On
Demand |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
63,322 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Joshua Bauman |
|
|
11.0 |
% |
|
October
21, 2022 |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
169,710 |
|
|
|
|
10.0 |
% |
|
August
9, 2024 |
|
|
120,776 |
|
|
|
990 |
|
|
|
121,766 |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Series N convertible notes |
|
|
6.0 |
% |
|
On
Demand |
|
|
3,229,000 |
|
|
|
999,161 |
|
|
|
4,228,161 |
|
|
|
4,041,813 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
3,419,776 |
|
|
$ |
1,000,151 |
|
|
$ |
4,419,927 |
|
|
$ |
5,269,250 |
|
Leonite
Capital, LLC
On
July 12, 2020, the Company entered into a Senior Secured Convertible Note agreement with Leonite for $440,000 with an original issue
discount of $40,000 for gross proceeds of $400,000, the initial tranche advanced will be for cash of $200,000 plus the OID
of $20,000, the remaining advances will be at the discretion of the Leonite. The loan bears interest at 6.5% per annum and matures
on June 12, 2021. The Company is required to make monthly payments of the accrued interest on the advances made. The note is convertible
into common shares at the option of the holder at $0.10 per share, or 80% multiplied by the price per share paid in subsequent financings
or after a six month period from the effective date at 60% of the lowest trading price during the preceding 21 consecutive trading days.
The note has both conversion price protection and anti-dilution protection provisions.
On
February 28, 2022, in terms of a conversion notice, Leonite converted the principal sum of $149,250 of the Leonite Note into 150,000,000 shares
of common stock at a conversion price of $0.0010 per share.
On
March 1, 2023, the Company entered into a forbearance agreement with Leonite whereby the parties agreed to extend the maturity date of
the note to June 8, 2023, the Company will continue to pay interest on the note, until repaid. On August 4, 2023, the Company settled
all outstanding liabilities owing to Leonite Capital and Leonite Fund I, LP, for gross proceeds of $1,449,000.
Leonite
Fund I, LP
Effective
June 1, 2022, the Company entered into a Note Exchange Agreement whereby the convertible promissory notes entered into with Labrys Fund
LP on May 7, 2021, with an outstanding principal balance of $341,000, and on June 2, 2021, with an outstanding principal balance of $230,000
and accrued interest thereon of $25,300, were exchanged for a new Senior Secured Convertible Promissory note in the principal amount
of $745,375, including an OID of $149,075. The Note matured on March 1, 2023, and bore interest at the minimum of 10% per annum or the
Wall Street Journal quoted prime rate plus 5.75%.
Interest
is payable monthly and the note may be prepaid with a prepayment penalty of 10%. The note is convertible into common stock
at a fixed conversion price of $0.01 per share, subject to anti-dilution adjustments and a fundamental transaction clause allowing the
note holder to receive the same consideration as common stockholders would receive.
The
convertible note is secured by all of the assets of Ethema Health Corporation and Addiction Recovery Institute of America, LLC.
On
March 1, 2023, the Company entered into a forbearance agreement with Leonite whereby the parties agreed to extend the maturity date of
the note to June 8, 2023, the Company will continue to pay interest on the note, until repaid. On August 4, 2023, the Company
settled all outstanding liabilities owing to Leonite Capital and Leonite fund I, L.P. for gross proceeds of $1,449,000.
ETHEMA
HEALTH CORPORATION
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
9. Short-term
Convertible Notes (continued)
Auctus
Fund, LLC
On
August 7, 2019, the Company, entered into a Securities Purchase Agreement with Auctus Fund, LLC, pursuant to which the Company issued
a Convertible Promissory Note in the aggregate principal amount of $225,000. The Note had a maturity date of May 7, 2020 and
bore interest at the rate of ten percent per annum from the date on which the Note was issued until the same became due and payable,
whether at maturity or upon acceleration or by prepayment or otherwise. The Company had the right to prepay the Note in terms of agreement.
The outstanding principal amount of the Note is convertible at any time and from time to time at the election of Auctus Fund, LLC during
the period beginning on the date that is 180 days following the issue date into shares of the Company’s common stock at a conversion
price equal to 60% of the lowest closing bid price of the Company’s common stock for the thirty trading days prior to conversion.
On
June 15, 2020, The Company entered into an amended agreement with Auctus whereby the Company agreed to discharge the principal amount
of the note by nine equal monthly installments of $25,000 commencing in October 2020. During the year ended December 31, 2021, the
Company repaid Auctus the principal sum of $50,000.
During
March 2022, the Company paid $20,000 of principal on the convertible note, thereby reducing the principal outstanding to $80,000. The
note matured May 7, 2020, Auctus Fund LLC has not declared a default and we are in discussion with the lender on settling the note.
During
February 2023, the Company paid $10,000 of principal on the convertible note, thereby reducing the principal outstanding to $70,000.
The note matured May 7, 2020, Auctus Fund LLC has not declared a default and we are in constant in constant discussion with the lender
on settling the note.
Ed
Blasiak
On
September 14, 2020, the Company entered into a Securities Purchase Agreement with Ed Blasiak (“Blasiak”), pursuant to which
the Company issued a senior secured convertible promissory note in the aggregate principal amount of $55,000, including an original issue
discount of $5,000. The note bears interest at 6.5% per annum and matured on September 14, 2021. The note is senior to any
future borrowings and commencing on October 1, 2020 the Company will make monthly payments of the accrued interest under the note. The
note may be prepaid at certain prepayment penalties and is convertible into shares of common stock at a conversion price at the option
of the holder at $0.001 per share, adjusted for anti-dilution provisions; or 80% of the price per share of subsequent equity financings
or; after six months 60% of the lowest trading price during the preceding six month period.
The
note had matured and was in technical default which had not been formally declared by Ed Blasiak. On August 4, 2023, the Company
settled the senior secured convertible promissory note owing to Ed Blasiak for proceeds of $65,450.
Joshua
Bauman
On
October 21, 2021, the Company entered into a Securities Purchase Agreement with Bauman, pursuant to which the Company issued a senior
secured convertible promissory note in the aggregate principal amount of $150,000, including an original issue discount of $16,250. The
note bears interest at 11.0% per annum, which is guaranteed and earned in full on issue date and matured on October 21, 2022.
The note is convertible into shares of common stock at a conversion price at the option of the holder at $0.001 per share, adjusted for
anti-dilution provisions.
The
note had matured and was in technical default which had not been formally declared by Mr. Bauman. On August 4, 2023, the Company
settled the senior secured convertible promissory note owing to Mr. Bauman for proceeds of $179,474.
On
August 9, 2023, the Company issued a convertible promissory note to Mr. Bauman, in the aggregate principal amount of $150,000. The note
bears interest at 10.0% per annum and matures on August 9, 2024. The note is convertible into shares of common stock at a conversion
price at the option of the holder at $0.001 per share, adjusted for anti-dilution provisions. The note is convertible into common stock
at the option of the holder after the expiration of six months from the issuance date, in addition, should the note reach its maturity
date, August 9, 2024, the note will automatically convert into shares of common stock at the conversion price, subject to anti-dilution
provisions.
During
November 2023 and December 2023, the company repaid $29,224 and $4,597 in principal and interest, respectively.
Series
N convertible notes
Between
January 28, 2019 and June 11, 2020, the Company closed several tranches of Series N Convertible notes in which it raised $3,229,000 in
principal from accredited investors through the issuance to the investors of the Company’s Series N convertible notes, in the total
original principal amount of $3,229,000, which Notes are convertible into the Company’s common stock at a conversion price of $0.08 per
share together with three year warrants to purchase up to a total of 52,237,500 shares of the Company’s common stock
at an exercise price of $0.12 per share. Both the conversion price under the Notes and the exercise price under the warrants are
subject to standard adjustment mechanisms. The notes matured one year from the date of issuance.
The
series N convertible notes matured and are in default. The Company is considering its options to settle these notes.
ETHEMA
HEALTH CORPORATION
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
10.
Short-term Notes
Leonite
Capital, LLC
Secured
Promissor